Pulmonx (LUNG) 10-Q 13 Nov 20 2020 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2020	Oct. 30, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2020
Document Transition Report	false
Entity File Number	001-39562
Entity Registrant Name	PULMONX CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	77-0424412
Entity Address, Address Line One	700 Chesapeake Drive
Entity Address, City or Town	Redwood City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94063
Country Region	1
City Area Code	650
Local Phone Number	364-0400
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	LUNG
Security Exchange Name	NASDAQ
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		35,668,953
Entity Central Index Key	0001127537
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 39,806	$ 14,767
Restricted cash		0
Short-term marketable securities	0	13,580
Accounts receivable, net	5,260	5,511
Inventory	9,288	5,612
Prepaid expenses and other current assets	1,037	1,601
Total current assets	55,622	41,071
Property and equipment, net	1,164	902
Goodwill	2,333	2,333
Intangible assets, net	431	524
Deferred offering costs	1,680	1,563
Right of use assets	9,489	6,561
Other long-term assets	525	579
Total assets	71,244	53,533
Current liabilities
Accounts payable	2,297	2,681
Accrued liabilities	8,844	9,463
Income taxes payable	158	233
Deferred revenue	92	173
Current lease liabilities	1,927	446
Derivative liabilities	1,856	1,165
Total current liabilities	15,174	14,161
Deferred tax liability	54	43
Long-term lease liabilities	8,250	6,403
Credit agreement	539	0
Term loan	16,763	14,965
Convertible notes	29,754	0
Total liabilities	70,534	35,572
Commitments and contingencies (Note 8)
Convertible preferred stock, $0.001 par value, 22,874,341 and 177,985,811 shares authorized as of September 30, 2020 and December 31, 2019; 17,797,026 and 17,583,150 shares issued and outstanding as of September 30, 2020 and December 31, 2019; liquidation value of $212,870 and $210,610 as of September 30, 2020 and December 31, 2019 (Note 11)	207,599	205,339
Stockholders’ deficit
Common stock, $0.001 par value, 200,000,000 shares authorized as of September 30, 2020 and 240,000,000 shares authorized as of December 31, 2019; 3,801,824 shares issued and outstanding as of September 30, 2020 and 2,100,203 shares issued and outstanding as December 31, 2019	4	2
Additional paid-in capital	24,896	21,750
Accumulated other comprehensive income	1,648	1,373
Accumulated deficit	(233,437)	(210,503)
Total stockholders’ deficit	(206,889)	(187,378)
Total liabilities, convertible preferred stock and stockholders’ deficit	$ 71,244	$ 53,533

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenue	$ 10,612	$ 9,104	$ 22,903	$ 22,248
Cost of goods sold	3,150	2,697	8,779	7,171
Gross profit	7,462	6,407	14,124	15,077
Operating expenses
Research and development	1,997	1,399	4,988	4,446
Selling, general and administrative	10,813	8,621	32,114	24,179
Total operating expenses	12,810	10,020	37,102	28,625
Loss from operations	(5,348)	(3,613)	(22,978)	(13,548)
Interest income	9	167	98	310
Interest expense	(1,103)	(460)	(2,914)	(1,867)
Other income (expense), net	2,631	(340)	3,052	(713)
Net loss before tax	(3,811)	(4,246)	(22,742)	(15,818)
Income tax expense	49	89	192	216
Net loss	(3,860)	(4,335)	(22,934)	(16,034)
Other comprehensive income
Currency translation adjustment	33	71	281	127
Change in unrealized (losses) gains on marketable securities	0	7	(6)	7
Total other comprehensive income	33	78	275	134
Comprehensive loss	$ (3,827)	$ (4,257)	$ (22,659)	$ (15,900)
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (1.37)	$ (2.41)	$ (10.33)	$ (9.21)
Weighted-average shares used in computing net loss per share attributable to common stockholder, basic and diluted (in shares)	2,814,798	1,800,286	2,220,734	1,740,072

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2018	12,648,919
Beginning balance at Dec. 31, 2018	$ 140,535
Ending balance (in shares) at Mar. 31, 2019	12,648,919
Ending balance at Mar. 31, 2019	$ 140,464
Beginning balance (in shares) at Dec. 31, 2018		1,719,446
Beginning balance at Dec. 31, 2018	(167,326)	$ 2	$ 21,139	$ 1,333	$ (189,800)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Series G-1 convertible preferred stock issuance costs	(71)
Issuance of common stock upon exercise of stock options (in shares)		4,328
Issuance of common stock upon exercise of stock options	5		5
Common stock retired during the year and repurchase of early exercised common stock options (in shares)		(414)
Common stock retired during the year and repurchase of early exercised common stock options	0
Change in shares subject to repurchase	5		5
Stock-based compensation expense	50		50
Currency translation adjustment	(17)			(17)
Net loss	(6,128)				(6,128)
Ending balance (in shares) at Mar. 31, 2019		1,723,360
Ending balance at Mar. 31, 2019	$ (173,411)	$ 2	21,199	1,316	(195,928)
Beginning balance (in shares) at Dec. 31, 2018	12,648,919
Beginning balance at Dec. 31, 2018	$ 140,535
Ending balance (in shares) at Sep. 30, 2019	17,583,150
Ending balance at Sep. 30, 2019	$ 205,339
Beginning balance (in shares) at Dec. 31, 2018		1,719,446
Beginning balance at Dec. 31, 2018	$ (167,326)	$ 2	21,139	1,333	(189,800)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock retired during the year and repurchase of early exercised common stock options (in shares)	(414)
Currency translation adjustment	$ 127
Change in unrealized (losses) gains on marketable securities	7
Net loss	(16,034)
Ending balance (in shares) at Sep. 30, 2019		2,037,842
Ending balance at Sep. 30, 2019	$ (182,838)	$ 2	21,527	1,467	(205,834)
Beginning balance (in shares) at Mar. 31, 2019	12,648,919
Beginning balance at Mar. 31, 2019	$ 140,464
Convertible Preferred Stock
Issuance of convertible preferred stock	$ 64,875
Ending balance (in shares) at Jun. 30, 2019	17,583,150
Ending balance at Jun. 30, 2019	$ 205,339
Beginning balance (in shares) at Mar. 31, 2019		1,723,360
Beginning balance at Mar. 31, 2019	(173,411)	$ 2	21,199	1,316	(195,928)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Series G-1 convertible preferred stock issuance costs	258
Issuance of common stock upon exercise of stock options (in shares)		36,500
Issuance of common stock upon exercise of stock options	53		53
Common stock retired during the year and repurchase of early exercised common stock options (in shares)		(812)
Common stock retired during the year and repurchase of early exercised common stock options	0
Change in shares subject to repurchase	(7)		(7)
Stock-based compensation expense	75		75
Currency translation adjustment	73			73
Net loss	(5,571)				(5,571)
Ending balance (in shares) at Jun. 30, 2019		1,759,048
Ending balance at Jun. 30, 2019	$ (178,788)	$ 2	21,320	1,389	(201,499)
Ending balance (in shares) at Sep. 30, 2019	17,583,150
Ending balance at Sep. 30, 2019	$ 205,339
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		278,794
Issuance of common stock upon exercise of stock options	341		341
Change in shares subject to repurchase	(206)		(206)
Stock-based compensation expense	72		72
Currency translation adjustment	71			71
Change in unrealized (losses) gains on marketable securities	7			7
Net loss	(4,335)				(4,335)
Ending balance (in shares) at Sep. 30, 2019		2,037,842
Ending balance at Sep. 30, 2019	$ (182,838)	$ 2	21,527	1,467	(205,834)
Beginning balance (in shares) at Dec. 31, 2019	17,583,150
Beginning balance at Dec. 31, 2019	$ 205,339
Convertible Preferred Stock
Issuance of convertible preferred stock	$ 2,260
Ending balance (in shares) at Mar. 31, 2020	17,797,026
Ending balance at Mar. 31, 2020	$ 207,599
Beginning balance (in shares) at Dec. 31, 2019	2,100,203	2,100,203
Beginning balance at Dec. 31, 2019	$ (187,378)	$ 2	21,750	1,373	(210,503)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		7,164
Issuance of common stock upon exercise of stock options	11		11
Change in shares subject to repurchase	2		2
Stock-based compensation expense	209		209
Currency translation adjustment	282			282
Change in unrealized (losses) gains on marketable securities	(5)			(5)
Net loss	(7,163)				(7,163)
Ending balance (in shares) at Mar. 31, 2020		2,107,367
Ending balance at Mar. 31, 2020	$ (194,042)	$ 2	21,972	1,650	(217,666)
Beginning balance (in shares) at Dec. 31, 2019	17,583,150
Beginning balance at Dec. 31, 2019	$ 205,339
Ending balance (in shares) at Sep. 30, 2020	17,797,026
Ending balance at Sep. 30, 2020	$ 207,599
Beginning balance (in shares) at Dec. 31, 2019	2,100,203	2,100,203
Beginning balance at Dec. 31, 2019	$ (187,378)	$ 2	21,750	1,373	(210,503)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)	1,711,621
Currency translation adjustment	$ 281
Change in unrealized (losses) gains on marketable securities	(6)
Net loss	$ (22,934)
Ending balance (in shares) at Sep. 30, 2020	3,801,824	3,801,824
Ending balance at Sep. 30, 2020	$ (206,889)	$ 4	24,896	1,648	(233,437)
Beginning balance (in shares) at Mar. 31, 2020	17,797,026
Beginning balance at Mar. 31, 2020	$ 207,599
Ending balance (in shares) at Jun. 30, 2020	17,797,026
Ending balance at Jun. 30, 2020	$ 207,599
Beginning balance (in shares) at Mar. 31, 2020		2,107,367
Beginning balance at Mar. 31, 2020	(194,042)	$ 2	21,972	1,650	(217,666)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		925
Issuance of common stock upon exercise of stock options	1		1
Change in shares subject to repurchase	63		63
Stock-based compensation expense	159		159
Currency translation adjustment	(34)			(34)
Change in unrealized (losses) gains on marketable securities	(1)			(1)
Net loss	(11,911)				(11,911)
Ending balance (in shares) at Jun. 30, 2020		2,108,292
Ending balance at Jun. 30, 2020	$ (205,765)	$ 2	22,195	1,615	(229,577)
Ending balance (in shares) at Sep. 30, 2020	17,797,026
Ending balance at Sep. 30, 2020	$ 207,599
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		1,703,532
Issuance of common stock upon exercise of stock options	2,645	$ 2	2,643
Common stock retired during the year and repurchase of early exercised common stock options (in shares)		(10,000)
Common stock retired during the year and repurchase of early exercised common stock options	0
Change in shares subject to repurchase	(460)		(460)
Stock-based compensation expense	518		518
Currency translation adjustment	33			33
Change in unrealized (losses) gains on marketable securities	0
Net loss	$ (3,860)				(3,860)
Ending balance (in shares) at Sep. 30, 2020	3,801,824	3,801,824
Ending balance at Sep. 30, 2020	$ (206,889)	$ 4	$ 24,896	$ 1,648	$ (233,437)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities
Net loss	$ (22,934)	$ (16,034)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense	886	197
Change in fair value of convertible preferred stock warrant liability	0	(10)
Change in fair value of derivative liabilities	(3,209)	408
Allowance for doubtful accounts	(7)	3
Inventory write-downs	380	250
Depreciation and amortization expense	355	253
Amortization of debt discount and debt issuance costs	901	22
Write-off of deferred offering costs	3,030	0
Amortization of premiums and discounts on short-term marketable securities	(35)	(22)
Loss on extinguishment of debt	0	(32)
Non-cash lease expense	955	574
Net changes in operating assets and liabilities:
Accounts receivable	336	(2,311)
Inventory	(3,944)	(2,139)
Prepaid expenses and other current assets	412	3
Other assets	71	3
Accounts payable	(166)	149
Accrued liabilities	310	2,056
Income taxes payable	(85)	63
Lease liabilities	(554)	(582)
Deferred tax liability	10	(35)
Deferred revenue	(83)	(110)
Net cash used in operating activities	(23,371)	(17,294)
Cash flows from investing activities
Purchases of investments	0	(18,966)
Maturities of short-term marketable securities	13,605	2,207
Purchases of property and equipment	(218)	(499)
Net cash provided by (used in) investing activities	13,387	(17,258)
Cash flows from financing activities
Proceeds from borrowing under term loans, net of payment of lender fees and costs	16,764	0
Proceeds from Credit Agreement	527	0
Repayment of term loans	(17,248)	0
Proceeds from the issuance of convertible note, net of payment of lender fees and costs (includes $0 and $6,000 from related party for the nine months ended September 30, 2020 and September 30, 2019, respectively)	32,950	6,000
Proceeds from Paycheck Protection Program loan	2,666	0
Repayment of Paycheck Protection Program loan	(2,666)	0
Debt issuance cost	(162)	0
Payments of deferred offering costs	(2,727)	(21)
Proceeds from issuance of Series G-1 convertible preferred stock, net of issuance costs of $329	0	39,671
Proceeds from exercise of warrants for Series C-1 convertible preferred stock	2,261	0
Proceeds from exercise of common stock options	2,722	399
Payments for the repurchase of early exercised common stock options	(21)	(12)
Net cash provided by financing activities	35,066	46,037
Effect of exchange rate changes on cash and cash equivalents	188	121
Net increase in cash and cash equivalents	25,270	11,606
Cash, cash equivalents and restricted cash, at beginning of the period	14,767	4,124
Cash, cash equivalents and restricted cash, at end of the period	40,037	15,730
Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets:
Cash, cash equivalents and restricted cash in consolidated balance sheets	40,037	15,730
Supplemental non-cash items:
Increases in repurchase rights of common stock	(395)	(208)
Purchases of property and equipment in accounts payable	288	63
Accrued interest for convertible note	788	496
Issuance of derivative instrument related to convertible notes	3,900	0
Amount of debt converted	0	25,133
Operating lease right of use asset recorded on the adoption of ASC 842	0	1,181
Right-of-use assets obtained in exchange for lease liabilities	3,882	0
Supplemental disclosure of cash flow information:
Cash paid for income taxes	149	187
Cash paid for interest	$ 2,880	$ 1,061

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Convertible preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized (in shares)	22,874,341	177,985,811
Convertible preferred stock, shares issued (in shares)	17,797,026	17,583,150
Convertible preferred stock, shares outstanding (in shares)	17,797,026	17,583,150
Liquidation value	$ 212,870	$ 210,610
Stockholders’ deficit
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	240,000,000
Common stock, shares issued (in shares)	3,801,824	2,100,203
Common stock, shares outstanding (in shares)	3,801,824	2,100,203

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
Statement of Stockholders' Equity [Abstract]
Payments for issuance costs	$ (258)	$ 71

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Statement of Cash Flows [Abstract]
Proceeds from related party	$ 6,000	$ 0
Payments for issuance costs		$ 329

Formation and Business of the C

Formation and Business of the Company	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Formation and Business of the Company	Formation and Business of the Company The Company Pulmonx Corporation (the “Company”) was incorporated in the state of California in December 1995 as Pulmonx and reincorporated in the state of Delaware in December 2013. The Company is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The Company’s solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat a broad pool of patients for whom medical management has reached its limits and either do not want or are ineligible for surgical approaches. The Company has subsidiaries in the Cayman Islands, Germany, Switzerland, Australia, the United Kingdom, the Netherlands, Italy, France and Hong Kong. Initial Public Offering On September 30, 2020, the Company’s registration statement on Form S-1 (File No. 333-248635) relating to its initial public offering (“IPO”) of common stock became effective. The IPO closed on October 5, 2020 at which time the Company issued 11,500,000 shares of its common stock at a price of $19.00 per share, which included the issuance of shares in connection with the exercise by the underwriters of their option to purchase up to 1,500,000 additional shares (see Note 15). The Company received an aggregate of $218.5 million gross proceeds, before underwriting discounts, commissions and offering costs, and approximately $201.4 million in net proceeds after deducting underwriting discounts and commissions and offering costs. In addition, upon closing the IPO, all outstanding shares of the Company’s convertible preferred stock converted into 17,797,026 shares of common stock. In connection with the completion of its IPO, on October 5, 2020, the Company’s certificate of incorporation was amended and restated to provide for 200,000,000 authorized shares of common stock with a par value of $0.001 per share and 10,000,000 authorized shares of preferred stock with a par value of $0.001 per share. The unaudited interim condensed consolidated financial statements as of September 30, 2020, including share and per share amounts, do not give effect to the IPO, as it closed subsequent to September 30, 2020. Liquidity and Going Concern The Company has incurred operating losses and negative cash flows from operations to date and has an accumulated deficit of $233.4 million as of September 30, 2020. During the nine months ended September 30, 2020 and September 30, 2019, the Company used $23.4 million and $17.3 million of cash in its operating activities, respectively. As of September 30, 2020, the Company had cash and cash equivalents of $39.8 million. Historically, the Company’s activities have been financed through private placements of equity securities and debt. On October 5, 2020, the Company completed an IPO in which the Company issued and sold 11,500,000 shares of its common stock, which includes 1,500,000 shares issued and sold pursuant to the exercise of the underwriters’ option to purchase additional shares, at a public offering price of $19.00 per share, for aggregate gross proceeds of $218.5 million. The Company received approximately $201.4 million in net proceeds after deducting underwriting discounts and commissions and offering costs. The Company’s condensed consolidated financial statements have been prepared on the basis of the Company continuing as a going concern for the next 12 months. Management believes that the Company’s existing cash and cash equivalents, together with the net proceeds from the IPO, will allow the Company to continue its operations for at least the next 12 months from the date of the issuance of these unaudited interim condensed consolidated financial statements. Impact of the COVID-19 Pandemic The Company has been actively monitoring the novel coronavirus, or COVID-19, situation and its impact. In response to the pandemic, numerous state and local jurisdictions have imposed “shelter-in-place” orders, quarantines and other restrictions. In the United States, governmental authorities have recommended, and in certain cases

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The Company’s unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). Reverse Stock Split On September 22, 2020, the Company effected a 1-for-10 reverse stock split of the Company’s common stock and convertible preferred stock. The par value and authorized shares of common stock were not adjusted as a result of the reverse stock split. All issued and outstanding common stock, convertible preferred stock, stock options and per share amounts contained in the accompanying financial statements and notes to the financial statements have been retroactively adjusted to give effect to the reverse stock split for all periods presented. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Unaudited Interim Financial Information The condensed consolidated balance sheet as of December 31, 2019 was derived from the Company’s audited financial statements, but does not include all disclosures required by GAAP. The accompanying unaudited condensed consolidated financial statements as of September 30, 2020 and for the three and nine months ended September 30, 2020 and 2019, have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. Accordingly, these financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2019 and notes thereto, included in the Company’s final prospectus for the IPO filed with the SEC pursuant to Rule 424(b)(4) on September 30, 2020 (“final prospectus”). In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company’s condensed consolidated financial position as of September 30, 2020 and condensed consolidated results of operations and cash flows for the three and nine months ended September 30, 2020 and 2019 have been made. The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2020. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. Significant estimates and assumptions include reserves and write-downs related to inventories, the recoverability of long term assets, valuation of equity instruments and equity-linked instruments, valuation of common stock, stock-based compensation, valuation of the convertible preferred stock warrant liability and derivative liability, intangible assets, goodwill, debt and related features, deferred tax assets and related valuation allowances and impact of contingencies. Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. The convertible preferred stock warrant liability and derivative liabilities are carried at fair value based on unobservable market inputs. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the term loan and convertible note approximates their fair value. The fair value of marketable debt securities is estimated using Level 2 inputs based on their quoted market values (Note 4). Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash, cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents balances with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance Corporation (“FDIC”) insured limits. As of September 30, 2020 and December 31, 2019, the Company also had cash on deposit with foreign banks of approximately $5.0 million and $5.2 million, respectively, that was not federally insured. The Company earns revenue from the sale of its products to distributors and other customers such as hospitals. Sales of Zephyr Valves and delivery catheters accounted for most of the Company’s revenue for the nine months ended September 30, 2020 and 2019. The Company’s accounts receivable are derived from revenue earned from distributors and customers. The Company performs ongoing credit evaluations of its customers’ and distributors’ financial condition and generally requires no collateral from its customers and distributors. At September 30, 2020 and December 31, 2019, no customer or distributor accounted for more than 10% of accounts receivable or revenue. The Company relies on single source suppliers for the components, sub-assemblies and materials for its products. These components, sub-assemblies and materials are critical and there are no or relatively few alternative sources of supply. The Company’s suppliers have generally met the Company’s demand for their products and services on a timely basis in the past. Deferred Offering Costs Deferred offering costs, consisting of legal, accounting and other fees and costs relating to the Company’s planned IPO, are capitalized and recorded on the balance sheet. The deferred offering costs will be offset against the proceeds received upon the closing of the planned IPO. In the event that the Company’s plans for an IPO are terminated, all of the deferred offering costs will be written off within operating expenses in the Company’s statements of operations and comprehensive loss. As of December 31, 2019, $1.6 million of deferred offering costs were recorded on the consolidated balance sheet. During the nine months ended September 30, 2020, the Company wrote off deferred offering costs of $3.0 million as, in May 2020, the Company withdrew its registration statement that was filed with the SEC in February 2020. As of September 30, 2020, $1.7 million of deferred offering costs were recorded on the consolidated balance sheet. Foreign Currency Translation and Transaction Gains and Losses The functional currencies of the Company’s wholly owned subsidiaries in the Cayman Islands and the Netherlands are the U.S. dollar. The functional currencies of the Company’s wholly owned subsidiaries in Switzerland, Germany, Australia, the United Kingdom, France and Hong Kong are the Swiss franc. The functional currency of the Company’s subsidiary in Italy is the Euro. Accordingly, asset and liability accounts of Switzerland, Germany, Australia, the United Kingdom, Italy and Hong Kong operations are translated into U.S. dollars using the current exchange rate in effect at the balance sheet date and equity accounts are translated into U.S. dollars using historical rates. The revenues and expenses are translated using the average exchange rates in effect during the period, and gains and losses from foreign currency translation adjustments are included as a component of accumulated other comprehensive income in the consolidated balance sheet. Foreign currency translation adjustments are recorded in other comprehensive income (loss) in the consolidated statements of operations and comprehensive loss and was less than $0.1 million and $0.1 million during the three months ended September 30, 2020 and 2019, respectively, and $0.3 million and $0.1 million during the nine months ended September 30, 2020 and 2019, respectively. Foreign currency transaction gains and losses are included in other income (expense), net in the consolidated statements of operations and comprehensive loss and was $(0.1) million and $0.2 million during the three months ended September 30, 2020 and 2019, respectively, and $0.2 million and $0.4 million during the nine months ended September 30, 2020 and 2019, respectively. Net Loss per Share Attributable to Common Stockholders Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, convertible preferred stock, stock options, common stock subject to repurchase related to early exercise of stock options, convertible preferred stock warrants and convertible note are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the convertible preferred stock is considered a participating security because it participates in dividends with common stock. The Company also considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities, because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of all series of convertible preferred stock and the holders of the shares issued upon early exercise of stock options subject to repurchase do not have a contractual obligation to share in the Company’s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In August 2018, FASB issued ASU 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement . This ASU amends the disclosure requirement in ASC 820, Fair Value Measurement , by adding, changing or removing certain disclosures. This ASU applies to all entities that are required under this guidance to provide disclosure about recurring or nonrecurring fair value measurements. The amendments require new disclosures related to: changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period; range and weighted-average of significant unobservable inputs used to develop Level 3 fair value measurements. In addition, there are certain changes in disclosure requirements in the existing guidance. For all entities, this ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2018-13 as of January 1, 2020 and the adoption had no material impact on the Company’s consolidated financial statements. In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other: Simplifying the Test for Goodwill Impairment . The amendments eliminate Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. The amendments also eliminate the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. This ASU is effective for public business entities for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company adopted ASU 2017-04 as of January 1, 2020 and the adoption had no material impact on the Company’s consolidated financial statements. Recent Accounting Pronouncements Not Yet Adopted In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848) (“ASU 2020-04”). The amendments in ASU 2020-04 provide optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in ASU 2020-04 are effective for all entities as of March 12, 2020 through December 31, 2022. An entity may elect to apply the amendments for contract modifications by Topic or Industry Subtopic as of any date from the beginning an interim period that includes or is subsequent to March 12, 2020, or prospectively from the date that the financial statements are available to be issued. Once elected for a Topic or an Industry Subtopic, the amendments must be applied prospectively for all eligible contract modifications for that Topic or Industry Subtopic. The Company may elect to apply ASU 2020-04 as its contracts referenced in London Interbank Offered Rate (“LIBOR”) are impacted by reference rate reform. The Company is currently evaluating the impact of the adoption of this ASU on the Company’s consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40)—Accounting For Convertible Instruments and Contracts in an Entity's Own Equity (“ASU 2020-06”). ASU 2020-06 simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. ASU 2020-06 also simplifies the diluted net income per share calculation in certain areas. This ASU is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years, with early adoption permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently evaluating the impact of the adoption of this principle on the Company’s consolidated financial statements. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This ASU is effective for public business entities for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently evaluating the impact of the adoption of ASU 2019-12 on the Company’s consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses . This new guidance will require financial instruments to be measured at amortized cost, and trade accounts receivable to be presented at the net amount expected to be collected. The new model requires an entity to estimate credit losses based on historical information, current information and reasonable and supportable forecasts, including estimates of prepayments. In November 2019, the FASB issued ASU 2019-10, according to which, the new standard is effective for public business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies (“SRC”) as defined by the SEC, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. For all other entities , the new standard is effective for fiscal years beginning after December 15, 2022, and interim periods within that fiscal year. Early adoption is permitted. The Company is a SRC for fiscal year 2019 and 2020. The Company is currently evaluating the impact of the new standard on the Company’s consolidated financial statements.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities are as follows: Level 1 – Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date. Level 2 – Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; Level 3 – Unobservable inputs for the asset or liability only used when there is little, if any, market activity for the asset or liability at the measurement date. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis – Financial assets and liabilities held by the Company measured at fair value on a recurring basis include money market funds, short-term marketable securities, convertible preferred stock warrant liability and derivative liabilities. Assets and Liabilities Measured and Recorded at Fair Value on a Nonrecurring Basis – The Company determines the fair value of long-lived assets held and used, such as intangible assets, by reference to independent appraisals, quoted market prices (e.g. an offer to purchase) and other factors. An impairment charge is recorded when the carrying value of the asset exceeds its fair value. As noted above, there have been no impairment charges recorded to date. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the term loan and convertible notes approximates their fair value and is classified as a Level 2 liability. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The following tables summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): September 30, 2020 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 10,133 $ — $ — $ 10,133 Cash equivalents 10,133 — — 10,133 Total financial assets $ 10,133 $ — $ — $ 10,133 Liabilities: Success fee derivative liability $ — $ — $ 1,856 $ 1,856 2020 Notes derivative liability — — — — Total financial liabilities $ — $ — $ 1,856 $ 1,856 December 31, 2019 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 6,318 $ — $ — $ 6,318 Commercial paper — 1,000 — 1,000 Cash equivalents 6,318 1,000 — 7,318 Corporate bonds — 7,105 — 7,105 Commercial paper — 6,475 — 6,475 Short-term marketable securities — 13,580 — 13,580 Total financial assets $ 6,318 $ 14,580 $ — $ 20,898 Liabilities: Preferred stock warrant liability $ — $ — $ — $ — Success fee derivative liability — — 1,165 1,165 Total financial liabilities $ — $ — $ 1,165 $ 1,165 The Company had no marketable securities as of September 30, 2020. The Company values the convertible preferred stock warrant liability (Note 10) using the Black-Scholes Merton option-pricing model. The expected term for these warrants is based on the remaining contractual life of these warrants. The expected volatility assumption was determined by examining the historical volatility for industry peers, as the Company does not have a trading history for its common stock. The risk-free interest rate assumption is based on U.S. Treasury investments whose term is consistent with the expected term of the warrants. The expected dividend assumption is based on the Company’s history and expectation of dividend payouts. The fair value of the Series C-1 convertible preferred stock warrants was determined using the following assumptions: December 31, 2019 Risk-free interest rate 1.6 % Remaining contractual life (in years) 0.1 Dividend yield 0 % Volatility 57.5 % Derivative liabilities include derivatives associated with the Company’s Success Fee Agreement with Oxford Finance LLC (Note 6) and the 2020 Notes derivative liability (Note 6). The Company valued the Success Fee derivative liability based on the Success Fee amount of $1.9 million and the probability and estimated timing of a liquidity event. The probability of occurrence of a Liquidity Event was estimated to be up to 99% and 65% before the expiration of the agreement as of September 30, 2020 and December 31, 2019, respectively. Changes in the estimated probability may result in an increase or decrease in the fair value of the derivative liability. The Company valued the 2020 Notes derivative liability using the a “with and without” methodology. The “with and without” methodology involves valuing the convertible note on an as is basis and then valuing the 2020 Notes without each individual embedded derivative. The difference between the value of the 2020 Notes with the embedded derivatives and the value without each individual embedded derivative equals the fair value of that embedded derivative. In April 2020, the Company valued the embedded derivatives using a Monte Carlo Simulation (“MCS”). The first step of each simulation was to forecast the Company’s Series G-1 convertible preferred stock price through the expiration of the 2020 Notes. In order to estimate the future share price of the Series G-1 convertible preferred stock, The Company applied a “random walk” model based upon a Geometric Brownian Motion process with a constant drift. The fair value of the 2020 Notes derivative liability was determined using the following assumptions: April 17 2020 Risk-free interest rate 0.2 % Current Series G-1 convertible preferred stock value per share $ 0.84 Series G-1 convertible preferred stock volatility 34.4 % As of September 30, 2020, the Company assumed the 2020 Notes would be converted pursuant to a qualified initial public offering (Note 6), as the IPO was highly likely to occur as of September 30, 2020. As a result, the Company concluded that the 2020 Notes derivative had no value because value of the notes with and without the such derivative was the same. The change in fair value of the convertible preferred stock warrant liability and derivative liabilities is summarized below (in thousands): Convertible Preferred Stock Warrant Liability Success Fee Derivative Liability 2020 Notes Derivative Liability Beginning fair value, January 1, 2019 $ 12 $ 642 $ — Change in fair value (12) 523 — Ending fair value, December 31, 2019 $ — $ 1,165 $ — Beginning fair value, January 1, 2020 — 1,165 — Fair value at inception — — 3,900 Change in fair value — 691 (3,900) Ending fair value, September 30, 2020 $ — $ 1,856 $ —

Balance Sheet Components

Balance Sheet Components	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	Balance Sheet Components Cash and Cash Equivalents The Company’s cash and cash equivalents consist of the following (in thousands): September 30, December 31, 2020 2019 Cash $ 29,673 $ 7,449 Cash equivalents: Money market funds 10,133 6,318 Commercial paper — 1,000 Total cash and cash equivalents $ 39,806 $ 14,767 Inventory Inventory consists of the following (in thousands): September 30, December 31, 2020 2019 Raw materials $ 3,286 $ 1,950 Work in process 328 180 Finished goods 5,674 3,482 Total inventory $ 9,288 $ 5,612 Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following (in thousands): September 30, December 31, 2020 2019 Prepaid expenses $ 453 $ 436 Prepaid insurance 146 12 VAT receivable 246 387 Other current assets 192 766 Total prepaid expenses and other current assets $ 1,037 $ 1,601 Property and Equipment, Net Property and equipment, net consist of the following (in thousands): September 30, December 31, 2020 2019 Machinery and equipment $ 1,317 $ 1,269 Computer equipment and software 947 848 Furniture and fixtures 228 168 Leasehold improvements 58 57 Construction in progress 270 — Total 2,820 2,342 Less: accumulated depreciation (1,656) (1,440) Property and equipment, net $ 1,164 $ 902 Depreciation expense for the three months ended September 30, 2020 and September 30, 2019 was $0.1 million and $0.1 million, respectively. Depreciation expense for the nine months ended September 30, 2020 and September 30, 2019 was $0.3 million and $0.2 million, respectively. Goodwill Goodwill was $2.3 million as of September 30, 2020 and December 31, 2019 arising from the Company’s acquisition of Emphasys Medical, Inc, in March 2009. No goodwill impairment losses have been recognized since the acquisition. There were no acquisitions or dispositions of goodwill in nine months ended September 30, 2020 and 2019. The Company assesses goodwill for impairment annually, or more frequently, when events or changes in circumstances indicate there may be impairment. The widespread economic volatility resulting from the COVID-19 pandemic triggered impairment testing, and accordingly, the Company performed interim tests as of March 31 and June 30, 2020 and determined that goodwill was not impaired. Through September 30, 2020, there have been no events or changes in circumstances that indicated that the carrying value of goodwill may not be recoverable. As a result, no impairment charge was recorded during the quarter ended September 30, 2020. Intangible Assets Intangible assets consist of the following (in thousands): September 30, 2020 Gross Carrying Value Accumulated Amortization Net Carrying Value Developed technology $ 1,658 $ (1,272) $ 386 Trademarks 191 (146) 45 Total intangible assets $ 1,849 $ (1,418) $ 431 December 31, 2019 Gross Carrying Value Accumulated Amortization Net Carrying Value Developed technology $ 1,658 $ (1,188) $ 470 Trademarks 191 (137) 54 Total intangible assets $ 1,849 $ (1,325) $ 524 Amortization expense relating to the intangibles totaled less than $0.1 million during each three months ended September 30, 2020 and September 30, 2019, respectively. Amortization expense relating to the intangibles totaled $0.1 million during each nine months ended September 30, 2020 and September 30, 2019, respectively. Future amortization expense is as follows as of September 30, 2020 (in thousands): 2020 (remaining three months) $ 31 2021 123 2022 123 2023 123 2024 31 Total amortization expense $ 431 Accrued Liabilities Accrued liabilities consist of the following (in thousands): September 30, December 31, 2020 2019 Accrued employee bonuses and commissions $ 2,070 $ 3,064 Accrued vacation 1,690 1,098 Other accrued personnel related expenses 510 705 Accrued professional fees 1,736 1,337 Accrued interest 793 1,708 Sales taxes, franchise tax and VAT 427 762 Liability for early exercise of stock options 679 304 Other 939 485 Total accrued liabilities $ 8,844 $ 9,463

Long Term Debt and Convertible

Long Term Debt and Convertible Notes	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Long Term Debt and Convertible Notes	Long Term Debt and Convertible Notes Term Loan Oxford Finance Loan In August 2014, the Company entered into a Loan and Security Agreement with Oxford Finance LLC for up to $20.0 million in term loans (“Oxford Finance Loan”). In 2014, the Company borrowed $15.0 million and had the ability to draw an additional $5.0 million conditioned upon the achievement of a revenue milestone. The period during which the Company could draw an additional $5.0 million ended on November 30, 2015 without the Company borrowing the additional $5.0 million. The term loan bore interest at 8.96% and had a five-year term. The first 36 months were interest only payments followed by 24 months of equal payments of principal and interest. A final payment of 8.50% of the term loan amount was due at maturity and was being accreted using the effective interest rate method. The term loan was collateralized by assets, including cash and cash equivalents, accounts receivable and property and equipment. In May 2017, the Company entered into a First Amendment to Loan and Security Agreement that extended the interest only period through June 2018 and included an additional fee of $0.1 million due upon maturity. The amendment was accounted for as a debt modification and no gain or loss was recognized in the Company’s financial statements. In May 2018, the Company entered into Second and Third Amendments to Loan and Security Agreement that extended the interest only period through May 2019 and the maturity date to July 1, 2020. The amendment was accounted for as a debt modification and no gain or loss is recognized in the Company’s financial statements. The Company had the option to further extend the interest only period through March 2020 and the maturity date to May 1, 2021, provided that no event of default had occurred. The loan bore interest at an annual rate equal to the greater of (i) 8.71% and (ii) the sum of (a) the greater of the one month U.S. LIBOR rate on the last business day of the month that immediately precedes the month in which the interest will accrued and 1.85% plus (b) 6.86%. In May 2019, the Company elected to extend the interest only period of the term loan through March 2020 and the maturity date to May 2021. The incremental amendment fee, due at maturity, increased to $0.8 million from $0.4 million when the Company extended the interest only period through March 2020. As of December 31, 2019, the Oxford Finance Loan had an annual effective interest rate of 11.11% per year. In connection with the original agreement in August 2014, the Company also entered into the Success Fee Agreement. In the event of a sale or other disposition by the Company of all or substantially all of its assets, a merger or consolidation, or an initial public offering (a “Liquidity Event”), before the termination of the agreement on August 28, 2021, the Company is required to pay up to $2.5 million (the “Success Fee”) to Oxford Finance LLC. The Success Fee is equal to 6.25% of the term loan if the Liquidity Event occurs within 18 months of August 28, 2014, 8.75% if the Liquidity Event occurs after 18 months and within 3 years of August 28, 2014, and 12.50% if the Liquidity Event occurs after the third anniversary of August 28, 2014. As of September 30, 2020 and December 31, 2019, the maximum amount of Success Fee subject to a potential payout is $1.9 million. This agreement has been identified as a freestanding derivative under ASC 815, Derivatives (“Success Fee”) and is remeasured to its fair value at the end of each reporting period and any change in fair value is recognized as change in other income (expense), net in the statements of operations and comprehensive loss (Note 4). The fair value of the Success Fee derivative liability as of September 30, 2020 and December 31, 2019 was $1.9 million and $1.2 million, respectively. On October 5, 2020, in connection with the IPO, the Company paid $1.9 million pursuant to the Success Fee Agreement to Oxford Finance LLC. The Loan and Security Agreement contained customary affirmative and negative covenants and events of default. As of December 31, 2019, the Company was in default with a covenant in the Loan and Security Agreement resulting from its failure to maintain cash balances outside the United States within the levels set forth in the Loan and Security Agreement. This event of default was waived by Oxford Finance LLC. On February 20, 2020, the Company repaid its entire obligation under the term loan agreement with Oxford Finance LLC amounting to $17.3 million, including outstanding loan amount of $15.0 million, final payment of $1.3 million, amendment fees of $0.9 million and accrued interest of $0.1 million. The repayment of the obligation under the term loan agreement with Oxford Finance LLC was accounted as extinguishment and the Company recorded a loss on extinguishment of $0.4 million included in interest expense in the condensed consolidated statements of operations and comprehensive loss. The Oxford Finance Loan as of September 30, 2020 and as of December 31, 2019, consists of the following (in thousands): September 30, December 31, 2020 2019 Term loan $ — $ 15,000 Less: debt issuance costs — (27) Less: deferred financing costs — (8) Term loan $ — $ 14,965 During the three months ended September 30, 2020 and 2019, the Company recorded interest expense related to deferred financing and debt issuance costs of Oxford Finance Loan of $0 and less than $0.1 million, respectively. During each of the nine months ended September 30, 2020 and 2019, the Company recorded interest expense related to deferred financing and debt issuance costs of Oxford Finance Loan of less than $0.1 million. Interest expense on the term loan amounted to $0 and $0.4 million during the three months ended September 30, 2020 and 2019, respectively. Interest expense on the term loan amounted to $0.4 million and $1.3 million during the nine months ended September 30, 2020 and September 30, 2019, respectively. CIBC Loan On February 20, 2020, the Company executed a Loan and Security Agreement (the “CIBC Agreement”) with Canadian Imperial Bank of Commerce (“CIBC”) to raise up to $32.0 million in debt financing (“CIBC Loan”) consisting of $17.0 million advanced at the closing of the agreement (Tranche A), with the option to drawing up to an additional $8.0 million (Tranche B) on or before February 20, 2022. The term loan also provides for an additional financing tranche (Tranche C) of up to $7.0 million on or prior to February 20, 2022, which is conditioned upon achieving a trailing six-month revenue of at least $20.0 million as of the date of any Tranche C borrowing. The availability of Tranche B and Tranche C is further conditioned upon the joining of Pulmonx International Sàrl to the CIBC Agreement and the execution by Pulmonx International Sàrl of Swiss-law collateral documentation in favor of CIBC. The CIBC Loan originally had a five-year term maturing on February 20, 2025, which included 24 months of interest only payments followed by 36 months of equal payments of principal and interest. The interest only period can be extended to 36 months if the Company achieves three-month trailing revenue of at least $20.0 million as of February 20, 2022. The CIBC Loan bears interest at a floating rate equal to 1.0% above the Wall Street Journal Prime Rate at any time. The Tranche C loan will bear interest at a floating rate equal to 1.5% above the Wall Street Journal Prime Rate at any time. The CIBC Loan is collateralized by substantially all of the Company’s assets, including cash and cash equivalents, accounts receivable, intellectual property and equipment. The Company may prepay the loan, subject to certain requirements. The CIBC Agreement includes customary restrictive covenants, financial covenants, events of default and other customary terms and conditions. In April 2020, the Company entered into a First Amendment to CIBC Agreement that changed the maturity date to March 15, 2022, which shall be automatically extended to February 20, 2025 if the maturity of all outstanding convertible notes (see below) is extended to a date no earlier than May 21, 2025 or all convertible notes have been converted into convertible preferred stock of the Company. An amendment fee of $0.2 million was paid. The Tranche B drawing is conditioned to achieving a trailing six-month revenue of at least $15.0 million as of the date of any Tranche B borrowing. On the date of drawing Tranche B Loan or Tranche C Loan, the Company will pay a structuring fee in an amount equal to 1.0% of the amount of Tranche B Loan or Tranche C Loan. The amendment was accounted for as a debt modification and no gain or loss was recognized. As of September 30, 2020, the CIBC Loan had an annual effective interest rate of 5.16% per year. The financial covenants in the CIBC Agreement require the Company to have revenue for the trailing three-month period ending on March 31, 2021, and the last day of each June, September, December and March thereafter of not less than the greater of (i) the amount equal to 80% of the revenue for the trailing three-month period ending on such day, as set forth in the annual projections delivered to the CIBC, and approved by CIBC, and (ii) the revenue for the trailing three-month period ending on the last day of the month for which this covenant had most recently been tested prior to such day. Further, the Company on and at all times after April 17, 2020, maintain unrestricted cash in an aggregate amount equal to or greater than the Adjusted EBITDA loss as defined in the CIBC Agreement for the four-month period ending on any date of determination. As of September 30, 2020, the Company was in compliance with all the covenants contained in CIBC Agreement. The CIBC Loan as of September 30, 2020, consists of the following (in thousands): September 30, 2020 Term loan $ 17,000 Less: debt issuance costs (237) Term loan $ 16,763 The Company paid $0.3 million fees to the lender and third parties which is reflected as a discount on the CIBC Loan and is being accreted over the life of the term loan using the effective interest method. During the three months ended September 30, 2020 and nine months ended September 30, 2020, the Company recorded interest expense related to deferred financing and debt issuance costs of CIBC Loan of less than $0.1 million and $0.1 million, respectively. Interest expense on the CIBC Loan amounted $0.2 million and $0.5 million during the three and nine months ended September 30, 2020, respectively. Credit Agreement In April 2020, Pulmonx International Sàrl, a wholly-owned subsidiary of the Company, entered into a COVID-19 Credit Agreement with UBS Switzerland AG to receive up to 0.5 million Swiss Francs ($0.5 million U.S. dollar equivalent) under Swiss Federal Government program to mitigate the economic impact of the spread of the coronavirus. In May 2020, Pulmonx International Sàrl received $0.5 million Swiss Francs ($0.5 million U.S. dollar equivalent) under the COVID-19 Credit Agreement. The COVID-19 Credit Agreement will bear no interest and is payable within 60 months after receipt of funds. As of September 30, 2020, Pulmonx International Sàrl did not make any repayment of credit agreement. Paycheck Protection Program On April 16, 2020, the Company received $2.7 million in support from the Paycheck Protection Program (the “PPP”) established by the U.S. federal government as part of the CARES Act for the PPP. Because the U.S. government subsequently changed its position and guidelines related to the PPP and publicly traded companies, the Company repaid the loan on May 1, 2020. Convertible Notes In April 2020, the Company entered into a Note Purchase Agreement and Convertible Promissory Notes (collectively the “2020 Notes Agreement”) with certain investors (the “Lenders”) to issue convertible promissory notes (the “2020 Notes”) for a maximum aggregate amount of $66.0 million. In April 2020, the Company received $33.0 million in gross proceeds from issuance of the 2020 Notes. Upon meeting customary closing conditions, the Company can draw up to an additional $33.0 million, provided that any such draw be for no less than $5.0 million on or prior to April 17, 2022. All unpaid interest and principal will be due and payable upon request of the majority of Lenders (“Majority Holders”) on or after the earlier of April 17, 2022 or an event of default. The 2020 Notes accrue interest at a rate equal to 2.0% above the Wall Street Journal Prime Rate. The Company may prepay the 2020 Notes prior to April 17, 2022 only with the consent of the Majority Holders. In the event that the Company issues and sells shares of its convertible preferred stock to investors with total proceeds of not less than $30.0 million (excluding the conversion of the 2020 Notes or other convertible securities issued for capital raising purposes) (a “Qualified Financing”), then the outstanding principal amount of the 2020 Notes and any unpaid accrued interest shall automatically convert into the same class and series of convertible preferred stock sold in the Qualified Financing at a conversion price equal to the lesser of (i) the price per share paid for preferred stock in the Qualified Financing multiplied by either 85% if the conversion takes place within 18 months of the Initial Closing, or 80% otherwise, and (ii) $13.20 per share. In the event the Company sells shares of convertible preferred stock in a transaction that does not constitute a Qualified Financing (a “Non-Qualified Financing”), then the Majority Holders will have the option to treat such Non-Qualified Financing as a Qualified Financing; provided, that, the Majority Holders may not elect to convert the 2020 Notes held by any Significant Holder in the Non-Qualified Financing without such Significant Holder’s consent unless such Non-Qualified Financing (a) is led by an investor who is not currently a stockholder of the Company and (ii) raises at least $10.0 million in total proceeds from investors who are not currently stockholders of the Company. A Significant Holder is a holder of the 2020 Notes equal to or greater than $20 million. If there is an event of default, then the conversion of the 2020 Notes will be at a conversion price equal to the lesser of: a. the price per share paid for convertible preferred stock by the Investors in the Non-Qualified Financing multiplied by 75% , and b. the Series G-1 convertible preferred stock conversion price of $13.20 per share multiplied by 75%. Upon an initial public offering which results in net proceeds of not less than $30.0 million (a “Qualified IPO”), the outstanding 2020 Notes and any unpaid accrued interest shall automatically convert in whole into shares of the Company’s common stock at a conversion price equal to the lesser of (i) price per share paid for common stock in the Qualified IPO multiplied by either 85% if the conversion takes place within 18 months of the Initial Closing, or 80% otherwise, and (ii) $13.20 per share. Upon an initial public offering that does not constitute a Qualified IPO (a “Non-Qualified IPO”), the Majority Holders shall have the option to treat such Non-Qualified IPO as a Qualified IPO; provided that if there is an event of default, conversion of the 2020 Notes will be at a conversion price equal to the lesser of: a. the price per share paid for common stock in the Non-Qualified IPO multiplied by 75%, and b. the Series G- 1 convertible preferred stock conversion price of $13.20 per share multiplied by 75%. At any other time upon the election of the Majority Holders or a Significant Holder, the outstanding principal amount of the 2020 Notes and any unpaid accrued interest will convert in whole into the Company’s Series G-1 convertible preferred stock at the Series G-1 convertible preferred stock conversion price of $13.20 per share. If there is an event of default prior to selection of such option, the 2020 Notes will be converted at a conversion price equal to the Series G-1 convertible preferred stock conversion price of $13.20 per share multiplied by 75%. Upon any event of default, the Majority Holders can, at written notice to the Company, declare the principal and unpaid accrued interest under the 2020 Notes immediately due and payable. The 2020 Notes include embedded derivatives that are required to be bifurcated from the 2020 Notes and accounted for separately as a single, compound embedded derivative instrument under ASC 815, Derivatives (“2020 Notes derivative liability”). The Company determined that the share settled redemption in the case of a financing or an IPO discussed above represents an embedded derivative that is not clearly and closely related to the debt host and have accounted for these settlement alternatives as separate embedded derivative liability. The fair value of the 2020 derivative liability of $3.9 million was recorded on the issuance date of the 2020 Notes resulting in a debt discount, which is reported as a direct deduction from the face amount of the 2020 Notes. The 2020 derivative liability is remeasured to its fair value at the end of each reporting period and any change in fair value is recognized in other income (expense), net in the statements of operations and comprehensive loss (Note 4). The change in fair value of $3.3 million and $3.9 million during the three and nine months ended September 30, 2020, respectively, was recorded as a component of other income (expense), net in the condensed consolidated statements of operations and comprehensive loss. The fair value of the 2020 derivative liability as of September 30, 2020 was $0.0 million. At September 30, 2020, the Company retained the ability to draw up to an additional $33.0 million under the 2020 Notes Agreement until the maturity date in April 2022. The 2020 Notes consist of the following (in thousands): September 30, 2020 Convertible notes $ 33,000 Less: debt discount (3,246) Convertible notes $ 29,754 The Company incurred debt issuance costs of $0.1 million in connection with the 2020 Notes Agreement, which are reported on the balance sheet as a direct deduction from the face amount of the 2020 Notes. Debt discount of $0.1 million is amortized using the effective interest rate method over the term of the note and recorded as a non-cash interest expense. During the three and nine months ended September 30, 2020, the Company recorded interest expense of $0.9 million and $1.6 million on the 2020 Notes. As of September 30, 2020, the 2020 Notes had an annual effective interest rate of 12.33% per year. As of September 30, 2020, the accrued interest on the 2020 Notes of $0.8 million is included in accrued liabilities on the condensed consolidated balance sheet. The Company’s obligations with respect to the 2020 Notes are unsecured and subordinated to its obligations with respect to the CIBC Loan. The 2020 Notes have customary events of default. Contractual Maturities of Financing Obligations As of September 30, 2020, the aggregate future payments under the CIBC Loan, Credit Agreement, and 2020 Notes (including interest payments) are as follows (in thousands): 2020 (remaining three months) $ 182 2021 723 2022 53,702 2023 — 2024 — 2025 539 Total 55,146 Less: unamortized debt discount (3,483) Less: interest (4,607) Term loan, convertible notes, and credit agreement $ 47,056

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition The Company’s contract liabilities consist of deferred revenue for remaining performance obligations by the Company to the customer after delivery, which was $0.1 million and $0.2 million as of September 30, 2020 and December 31, 2019. The deferred revenue as of December 31, 2018 was $0.1 million, which was recognized as revenue during the year ended December 31, 2019. The deferred revenue as of December 31, 2019 was $0.2 million, which was recognized as revenue during the nine months ended September 30, 2020. The Company disaggregates its revenue by major geographic region, which has been disclosed in Note 14, “Segment Information”.

Leases, Lease Commitments and C

Leases, Lease Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Leases, Lease Commitments and Contingencies	Leases, Lease Commitments and Contingencies The Company has a lease for its headquarters location in Redwood City, California. In October 2019, the Company renewed its lease for the headquarters location in Redwood City, California for an additional five years commencing in August 2020 and expiring in July 2025. The monthly base rent during the renewed term will be $0.1 million and is subject to an annual increase of 3.5%. The Company is responsible for its share of real estate taxes, common area maintenance and management fees. The Company is eligible to receive a tenant improvement allowance of $0.2 million after commencement of the renewal term in August 2020, which was not received as of September 30, 2020. During 2013, the Company entered into a five-year lease for office facilities in Switzerland. The Company had an option to extend the lease through January 2022, which was not exercised by the Company. Per the lease terms, in the event the option to extend is not exercised, the lease remains in force and can be terminated with a 12-month’s notice. In April 2020, the Company executed a sublease for another office facility in Redwood City, California for a three-year term commencing on June 1, 2020. The lease agreement provides for early termination if the Company or Sublandlord elects to terminate the lease. The early termination may only occur on or after the expiration of the 18th full calendar month of the sublease term. In September 2020, the Company amended a sublease agreement entered in April 2020, to include additional facility space in Redwood City, California for a four-year term. The amendment was accounted as a separate sublease agreement. The sublease agreement contains a rent free period through February 14, 2021, after which rent is approximately $0.1 million per month. The sublease agreement can be extended for an additional twelve The Company has leases on two vehicle leases with lease terms ranging from 2 to 4 years. Operating lease cost consists of the following (in thousands): Nine Months Ended Operating lease cost $ 1,322 Short-term lease cost 9 Variable lease cost 227 Total lease cost $ 1,558 The following table summarizes a maturity analysis of the Company’s lease liabilities showing the aggregate lease payments as of September 30, 2020 (in thousands): 2020 (remaining 3 months) $ 522 2021 2,712 2022 2,069 2023 2,795 2024 2,589 2025 and beyond 1,007 Total minimum lease payments 11,694 Less: Amount of lease payments representing interest 1,517 Present value of future minimum lease payments $ 10,177 Less: Current lease liabilities $ 1,927 Long-term lease liabilities $ 8,250 The following table summarizes additional information related to the Company’s operating leases as of September 30, 2020 (in thousands, except weighted average data): Right of use asset $ 9,489 Weighted average remaining lease term (years) 4.37 Weighted average discount rate (percent) 6.1 The following table summarizes other supplemental information related to the Company’s operating leases (in thousands): Cash paid for amounts included in the measurement of lease liabilities included in cash flows used in operating activities $ 963 Right-of-use assets obtained in exchange for lease liabilities $ 3,882 Contingencies From time to time, the Company may be a party to various litigation claims in the normal course of business. Legal fees and other costs associated with such actions are expensed as incurred. The Company assesses, in conjunction with legal counsel, the need to record a liability for litigation and contingencies. Accrual estimates are recorded when and if it is determinable that such a liability for litigation and contingencies are both probable and reasonably estimable. In December 2018, a former distributor outside the United States filed suit alleging the Company’s subsidiary, PulmonX International Sàrl, conducted unfair competitive practices and violated the exclusive distribution rights as a result of the subsidiary’s termination of its distribution agreement. The complaint seeks pecuniary and non-pecuniary damages. The Company is in the initial stages of evaluating this matter and does not believe the impact of any such matter will be material to the Company’s results of operation or financial position.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesThe income tax expense for the nine months ended September 30, 2020 and 2019 was determined based upon estimates of the Company’s effective income tax rates in various jurisdictions. The difference between the Company’s effective income tax rate and the U.S. federal statutory rate is primarily attributable to state income taxes, foreign income taxes, the effect of certain permanent differences, and full valuation allowance against net deferred tax assets. The income tax expense for the nine months ended September 30, 2020 and 2019 relates primarily to state minimum income tax and income tax on the Company’s earnings in foreign jurisdictions. The Coronavirus Aid, Relief, and Economic Security (“CARES”) Act enacted in March 2020 did not provide an income tax benefit for the Company given its historical U.S. losses and a full valuation allowance against its net U.S. deferred tax assets.

Warrants for Convertible Prefer

Warrants for Convertible Preferred Stock	9 Months Ended
	Sep. 30, 2020
Warrants and Rights Note Disclosure [Abstract]
Warrants for Convertible Preferred Stock	Warrants for Convertible Preferred Stock A summary of the outstanding convertible preferred stock warrants is as follows (in thousands, except per share and share amounts): December 31, 2019 Exercise Price Per share Shares Fair Value of Liability Expiration Date Series C-1 convertible preferred stock warrants $ 10.57 215,291 $ — February 9, 2020 Series C-1 Convertible Preferred Stock Warrants In January and February 2020, warrants to purchase 213,876 shares of Series C-1 convertible preferred stock were exercised at an exercise price of $10.57 per share, yielding $2.3 million cash proceeds. Warrants to purchase 1,415 shares of Series C-1 convertible preferred stock warrants expired unexercised. As of September 30, 2020, no Series C-1 convertible preferred stock warrants were outstanding.

Convertible Preferred Stock

Convertible Preferred Stock	9 Months Ended
	Sep. 30, 2020
Temporary Equity Disclosure [Abstract]
Convertible Preferred Stock	Convertible Preferred Stock Under the Company’s Amended and Restated Certificate of Incorporation, the Company is authorized to issue up to 22,874,341 shares of convertible preferred stock. In April 2019, the Company issued 3,030,296 shares of Series G-1 convertible preferred stock at a price of $13.20 per share for cash proceeds of approximately $40.0 million. Additionally, the Company issued 1,903,935 shares of Series G-1 convertible preferred stock at a price of $13.20 per share upon the conversion of $25.1 million of convertible promissory notes and accrued interest with Boston Scientific Corporation. As of December 31, 2019, convertible preferred stock consists of the following (in thousands, except per share and share amounts): Series Number of Shares Authorized Number of Shares Issued and Outstanding Carrying Value (1) Liquidation Preference per Share Liquidation Value Series A-1 8,486,224 848,595 $ 8,135 $ 9.59 $ 8,138 Series B-1 24,224,676 2,422,444 23,130 10.57 25,605 Series C-1 39,422,980 3,726,974 37,306 10.57 39,395 Series D-1 9,400,000 939,979 10,268 11.00 10,340 Series E-1 9,230,768 923,049 11,896 13.00 12,000 Series F-1 37,878,787 3,787,878 49,800 13.20 50,000 Series G-1 49,342,376 4,934,231 64,804 13.20 65,132 Total 177,985,811 17,583,150 $ 205,339 $ 210,610 _______________ (1) Carrying values above are net of issuance costs. As of September 30, 2020, convertible preferred stock consists of the following (in thousands, except per share and share amounts): Series Number of Shares Authorized Number of Shares Issued and Outstanding Carrying Value (1) Liquidation Preference per Share Liquidation Value Series A-1 848,623 848,595 $ 8,135 $ 9.59 $ 8,138 Series B-1 2,422,468 2,422,444 23,130 10.57 25,605 Series C-1 3,942,298 3,940,850 39,566 10.57 41,655 Series D-1 940,000 939,979 10,268 11.00 10,340 Series E-1 923,077 923,049 11,896 13.00 12,000 Series F-1 3,787,879 3,787,878 49,800 13.20 50,000 Series G-1 10,009,996 4,934,231 64,804 13.20 65,132 Total 22,874,341 17,797,026 $ 207,599 $ 212,870 _______________ (1) Carrying values above are net of issuance costs. Dividends The holders of Series A-1, Series B-1, Series C-1, Series D-1, Series E-1, Series F-1 and Series G-1 convertible preferred stock are entitled to receive dividends, out of any assets legally available, prior and in preference to any declaration or payment of any dividend on the common stock of the Company, at a rate of $0.7672, $0.8456, $0.8456, $0.88, $1.04, $1.056 and $1.056 respectively, per share per year (as adjusted for stock splits, stock dividends, reclassifications and similar events) payable quarterly when, and as declared by the Board of Directors and are not cumulative. After payment of such dividends, any additional dividends shall be distributed the holders of Series A-1, Series B-1, Series C-1, Series D-1, Series E-1, Series F-1 and Series G-1 convertible preferred stock and common stock on a pro rata basis. No dividends have been declared to date. Liquidation In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, the holders of Series G-1 convertible preferred stock shall be entitled to receive, prior and in preference to any distribution of the assets of the Corporation or any such consideration to the holders of Series A-1, Series B-1, Series C-1, Series D-1, Series E-1 and Series F-1 convertible preferred stock or the holders of common stock, an amount equal to $13.20 per share (as adjusted for stock splits, stock dividends, reclassification and similar events) plus any declared but unpaid dividends. If upon the occurrence of such event, the assets and funds available are insufficient to permit the payment to the Series G-1 convertible preferred stockholders of the full preferential amounts, then the entire assets and funds of the Company legally available for distribution shall be distributed ratably among the holders of Series G-1 convertible preferred stock in proportion to the preferential amount each such holder is otherwise entitled to receive. After the payment in full of the Series G-1 liquidation preference, the holders of Series F-1 convertible preferred stock shall be entitled to receive, prior and in preference to any distribution of the assets of the Corporation or any such consideration to the holders of Series A-1, Series B-1, Series C-1, Series D-1 and Series E-1 convertible preferred stock or the holders of common stock, an amount equal to $13.20 per share (as adjusted for stock splits, stock dividends, reclassification and similar events) plus any declared but unpaid dividends. If upon the occurrence of such event, the assets and funds available are insufficient to permit the payment to the Series F-1 convertible preferred stockholders of the full preferential amounts, then the entire assets and funds of the Company legally available for distribution shall be distributed ratably among the holders of Series F-1 convertible preferred stock in proportion to the preferential amount each such holder is otherwise entitled to receive. After the payment in full of the Series F-1 liquidation preference, the holders of the Series E-1 convertible preferred stock shall be entitled to receive, prior and in preference to any distribution of the assets of the Corporation or any such consideration to the holders of Series A-1, Series B-1, Series C-1, and Series D-1 convertible preferred stock or the holders of common stock, an amount equal to $13.00 per share (as adjusted for stock splits, stock dividends, reclassification and similar events) plus any declared but unpaid dividends. If upon the occurrence of such event, after payment in full of the Series F-1 liquidation preference, the assets and funds available are insufficient to permit the payment to the Series E-1 convertible preferred stockholders of the full preferential amounts, then the entire assets and funds of the Company legally available for distribution shall be distributed ratably among the holders of Series E-1 convertible preferred stock in proportion to the preferential amount each such holder is otherwise entitled to receive. After the payment in full of the Series F-1 liquidation preference and the Series E-1 liquidation preference, the holders of Series A-1, Series B-1, Series C-1 and Series D-1 convertible preferred stock are entitled to receive, prior and in preference to any distribution of the assets of the Corporation or any such consideration to the holders of common stock, an amount equal to $9.59, $10.57, $10.57 and $11.00 per share (as adjusted for stock splits, stock dividends, reclassification and similar events) plus any declared but unpaid dividends. If upon the occurrence of such liquidation, the assets and funds of the Company legally available for distribution are insufficient to permit payment to such holders, then the entire remaining assets and funds shall be distributed ratably among such holders in proportion to the preferential amounts each such holder is otherwise entitled to receive. In the event of a Liquidation Transaction involving one or more third parties other than the purchaser of Series F-1 convertible preferred stock and after the payment in full of the liquidation preference required to be paid, the holders of the Series F-1 convertible preferred stock shall be entitled to receive, prior and in preference to any distribution of any of the assets of the Company or any such consideration to the holders of common stock an amount equal to the Additional Preference (as defined below) for each share of Series F-1 preferred stock then held by them. Upon the closing of a Liquidation Transaction, if the amounts earned or payable to the stockholders of the Corporation on or before the one (1) year anniversary of the closing of such Liquidation Transaction is (i) equal to or greater than $250.0 million but less than $300.0 million, the Additional Preference is equal to $3.30 per share (as adjusted for stock splits, stock dividends, reclassifications and the like) for each share of Series F-1 convertible preferred stock then held by them, (ii) equal to or greater than $300.0 million but less than $350.0 million, the Additional Preference is equal to $5.00 per share (as adjusted for stock splits, stock dividends, reclassifications and the like) for each share of Series F-1 preferred stock then held by them, and (iii) equal to or greater than $350.0 million, the Additional Preference is equal to $6.60 per share (as adjusted for stock splits, stock dividends, reclassifications and the like) for each share of Series F-1 convertible preferred stock then held by them. After liquidation preferences to the convertible preferred stockholders have been paid, and after the Additional Preference has been paid, if any, the remaining assets of the Company shall be distributed to the holders of common stock, Series A-1, Series B-1, Series C-1, Series D-1, Series E-1, Series F-1 and Series G-1 convertible preferred stock as if the convertible preferred shares were converted into common stock at then-applicable conversion price until the Series A-1, Series B-1, Series C-1, Series D-1, Series E-1, Series F-1 and Series G-1 convertible preferred stock have received an aggregate amount (including the initial preference amount) equal to $28.77, $31.71, $31.71, $33.00, $39.00, $39.60 and $39.60 per share (as adjusted for stock splits, stock dividends, reclassifications and similar events) plus any declared and unpaid dividends. The holders of common stock are entitled to receive ratably on a per-share basis all remaining assets. A liquidation, dissolution or winding up of the Company shall be deemed to be occasioned by, or include, (A) the sale, lease, license on an exclusive basis, conveyance or disposition (whether by merger or otherwise) by the Company of all or substantially all of the assets of the Company, or the sale or disposition of one or more subsidiaries of the Company if substantially all of the assets of the Company and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, or (B) the merger of the Company with or into any other corporation, limited liability company or other entity (other than a wholly-owned subsidiary of the Company); provided that none of the following shall be considered a Liquidation Transaction: (i) a merger effected exclusively for the purpose of changing the domicile of the Company, (ii) an equity financing effected for bona fide capital raising purposes in which the Company is the surviving entity or (iii) any transaction in which the stockholders of the Company immediately prior to the transaction own greater than 50% of the voting power of the Company or such other surviving or resulting entity (or if the Company or such other surviving or resulting entity is a wholly-owned subsidiary immediately following such acquisition, its parent). Voting The holders of convertible preferred stock shall have the same voting rights as the holders of common stock. The holders of common stock and the convertible preferred stock shall vote together as a single class on all matters. Each holder of common stock shall be entitled to one vote for each share of common stock held, and each holder of convertible preferred stock shall be entitled to the number of votes equal to the number of shares of common stock into which such shares of convertible preferred stock could be converted. As of September 30, 2020, the Board of Directors was comprised of eight members. For so long as there are outstanding at least 50,000 shares of Series A-1 convertible preferred stock (as adjusted for stock splits, reclassifications or similar events), the holders of Series A-1 convertible preferred stock, voting as a separate class, shall be entitled to elect one member of the Company’s Board of Directors. For so long as there are outstanding at least 50,000 shares of Series B-1 convertible preferred stock (as adjusted for stock splits, reclassifications or similar events), the holders of Series B-1 convertible preferred stock, voting as a separate class, shall also be entitled to elect two members of the Company’s Board of Directors. For so long as there are outstanding at least 50,000 shares of Series C-1 convertible preferred stock (as adjusted for stock splits, reclassifications or other similar transactions), the holders of Series C-1 convertible preferred stock, voting as a separate class, shall be entitled to elect two members of the Company’s Board of Directors. For so long as there are outstanding at least 50,000 shares of Series G-1 convertible preferred stock (as adjusted for stock splits, reclassifications or other similar transactions), the holders of Series G-1 convertible preferred stock, voting as a separate class, shall be entitled to elect one member of the Company’s Board of Directors. The holders of common stock and convertible preferred stock, voting together as a single class on an as-if-converted basis, shall be entitled to elect all remaining members of the Board of Directors. Conversion Each share of convertible preferred stock shall be convertible, at the option of the holder at any time after the date of issuance into the number of fully paid and non-assessable shares of common stock as determined by dividing the original issue price per share of each series of convertible preferred stock by the conversion price per share in effect for the shares of each series of convertible preferred stock at the time of conversion. The original conversion price per share of Series A-1, Series B-1, Series C-1, Series D-1, Series E-1, Series F-1 and Series G-1 convertible preferred stock shall be the original issue price, subject to adjustment, as described in the Company’s Amended and Restated Certificate of Incorporation. Each share of convertible preferred stock shall automatically be converted into shares of common stock at the conversion rate at the time in effect for such share immediately upon the earlier of (i) the Company’s sale of its common stock in a firm commitment underwritten public offering pursuant to a registration statement under the Securities Act of 1933 (“IPO”) which results in aggregate cash proceeds to the Company of not less than $30.0 million (net of underwriting discounts and commissions) (“Qualified IPO”) or (ii) the date specified by the vote or written consent of the holders of at least a majority of the then outstanding shares of convertible preferred stock, voting together as a single class. However, if the offering price to the public in a Qualified IPO (“Public Offering Price”) is less than 1.15 times of the conversion price of the Series G-1 convertible preferred stock in effect immediately prior to the Qualified IPO, then the conversion price for the Series G-1 convertible preferred stock shall be adjusted such that, upon the closing of the Qualified IPO, each share of Series G-1 convertible preferred stock will convert into that number of shares of common stock equal to the sum of (a) the number of shares of common stock issuable upon conversion of such share of Series G-1 convertible preferred stock immediately prior to the Qualified IPO (the “Pre-IPO Shares”) and (b) an additional number of shares of common stock determined by multiplying the Pre-IPO Shares by the quotient of (x) the difference between 1.15 times the conversion price of the Series G-1 convertible preferred stock immediately prior to the Qualified IPO and the Public Offering Price, divided by (y) the Public Offering Price.

Stockholders' Deficit

Stockholders' Deficit	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Stockholders' Deficit	Stockholders’ Deficit Common Stock As of September 30, 2020 and December 31, 2019, the Company’s certificate of incorporation authorized the Company to issue up to 200,000,000 and 240,000,000 shares of common stock, respectively. Common stockholders are entitled to dividends as and when declared by the Board of Directors, subject to the rights of holders of all classes of stock outstanding having priority rights as to dividends. There have been no dividends declared to date. The holder of each share of common stock is entitled to one vote. During 2019 the Company constructively retired 414 shares of common stock during the year that were abandoned. Shares Reserved for Future Issuance The Company has reserved shares of common stock for future issuances as follows: September 30, December 31, 2020 2019 Series A-1 convertible preferred stock outstanding 848,595 848,595 Series B-1 convertible preferred stock outstanding 2,422,444 2,422,444 Series C-1 convertible preferred stock outstanding 3,940,850 3,726,974 Series D-1 convertible preferred stock outstanding 939,979 939,979 Series E-1 convertible preferred stock outstanding 923,049 923,049 Series F-1 convertible preferred stock outstanding 3,787,878 3,787,878 Series G-1 convertible preferred stock outstanding 4,934,231 4,934,231 Warrants to purchase Series C-1 convertible preferred stock — 215,291 Convertible notes* 2,561,484 — Common stock options issued and outstanding 2,940,930 3,279,324 Common stock available for future grants 3,253,500 77,603 Total 26,552,940 21,155,368 _______________ * At September 30, 2020, the conversion of the 2020 Notes into convertible preferred stock was dependent on the outstanding loan balance including accrued interest and the per share conversion price (see Note 6). Upon closing the IPO, on October 5, 2020, the aggregate outstanding principal amount plus accrued interest under the 2020 Notes converted into 2,561,484 shares of common stock, which was used to determine the number of common stock issuable upon conversion of 2020 Notes. Stock Option Plan A summary of stock option activity for the nine months ended September 30, 2020 is set forth below: Outstanding Options Shares Available for Grant Number of Shares Weighted Average Exercise Price Balance, January 1, 2020 77,603 3,279,324 $ 1.66 Additional shares reserved 4,553,378 — Options granted (1,416,271) 1,416,271 6.36 Options exercised (1,711,621) 1.55 Options canceled (1) 38,790 (43,044) 4.67 Balance, September 30, 2020 3,253,500 2,940,930 $ 3.94 ______________ (1) Canceled stock options issued under the Company’s 2000 Stock Plan were canceled after the 2010 Stock Plan was approved and are not included in the shares available for grant as they were not returned to the stock option pool. The weighted average exercise price and aggregate intrinsic value of options outstanding and exercisable at September 30, 2020 was $3.94 per share and $44.3 million, respectively. September 30, 2020 Number of Shares Weighted Average Exercise Price Weighted Average Contractual Life (in Years) Options vested 1,137,472 $ 1.79 5.86 Options vested and expected to vest 2,940,930 $ 3.94 8.16 Total intrinsic value of options vested and expected to vest as of September 30, 2020 was $44.3 million. Early Exercise of Stock Options Under the terms of the individual option grants, all options are fully exercisable on the grant date, subject to the Company’s repurchase right at the original exercise price. Accordingly, options may be exercised prior to vesting. The shares are subject to the Company’s lapsing repurchase right upon termination of employment or over the options’ vesting period of generally four years at the original purchase price. The proceeds initially are recorded in other liabilities from the early exercise of stock options and are reclassified to additional paid-in capital as the Company’s repurchase right lapses. During the nine months ended September 30, 2020 and 2019, the Company repurchased 10,000 and 812 shares of common stock for less than $0.1 million and less than $0.1 million, respectively. As of September 30, 2020 and December 31, 2019, 381,387 and 199,810 shares were subject to repurchase, with an aggregate exercise price of $0.7 million and $0.3 million, respectively, and were recorded in other current liabilities. Total Stock-Based Compensation Stock-based compensation expense is reflected in the statements of operations and comprehensive loss as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Cost of goods sold $ 37 $ 4 $ 67 $ 13 Research and development 63 13 96 44 Selling, general and administrative 418 55 723 140 Total $ 518 $ 72 $ 886 $ 197 As of September 30, 2020, there was $14.3 million of unrecognized compensation costs related to non-vested common stock options, expected to be recognized over a weighted-average period of 2.41 years.

Net Loss per Share Attributable

Net Loss per Share Attributable to Common Stockholders	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Net Loss per Share Attributable to Common Stockholders	Net Loss per Share Attributable to Common Stockholders The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders which excludes shares which are legally outstanding, but subject to repurchase by the Company (in thousands, except share and per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Numerator Net loss attributable to common stockholders $ (3,860) $ (4,335) $ (22,934) $ (16,034) Denominator Weighted-average common stock outstanding 2,951,564 1,825,452 2,389,145 1,761,714 Less: weighted-average common shares subject to repurchase (136,766) (25,166) (168,411) (21,642) Weighted-average common shares used to compute basic and diluted net loss per share 2,814,798 1,800,286 2,220,734 1,740,072 Net loss per share attributable to common stockholders, basic and diluted $ (1.37) $ (2.41) $ (10.33) $ (9.21) The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company’s net loss, in common stock equivalent shares: As of September 30, 2020 2019 Convertible preferred stock 17,797,026 17,583,150 Convertible preferred stock warrants — 215,291 Options to purchase common stock 2,940,930 2,703,723 Unvested early exercised common stock options 381,387 175,331 Convertible notes* 2,561,484 — Total 23,680,827 20,677,495

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Segment Information	Segment InformationThe chief operating decision maker for the Company is the Chief Executive Officer. The Company’s Chief Executive Officer reviews financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of allocating resources and evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, the Company has determined that it has a single reportable and operating segment structure. The Company’s Chief Executive Officer evaluates performance based primarily on revenue in the geographic locations in which the Company operates. Revenue by geographic area is based on the billing address of the customer. The following table sets forth the Company’s revenue by geographic area (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Europe, Middle-East and Africa (“EMEA”) $ 4,440 $ 4,698 $ 9,703 $ 13,441 Asia Pacific 827 915 1,846 2,609 Other International — 86 39 197 United States 5,345 3,405 11,315 6,001 Total $ 10,612 $ 9,104 $ 22,903 $ 22,248 Long-lived assets by geographic area are based on physical location of those assets. The following table sets forth the Company’s long-lived assets by geographic area (in thousands): September 30, December 31, 2020 2019 United States $ 1,129 $ 852 EMEA 28 40 Asia Pacific 7 10 Total $ 1,164 $ 902

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On October 5, 2020, the Company paid $1.9 million pursuant to the Success Fee Agreement to Oxford Finance LLC. On October 5, 2020, upon the closing of IPO, the Company issued 11,500,000 shares of its common stock at a price of $19.00 per share, which included the issuance of shares in connection with the exercise by the underwriters of their option to purchase 1,500,000 additional shares. The Company received net proceeds of $201.4 million after deducting underwriting discounts, commissions, and offering costs. In connection with the completion of its IPO, on October 5, 2020, the Company’s certificate of incorporation was amended and restated to provide for 200,000,000 authorized shares of common stock with a par value of $0.001 per share and 10,000,000 authorized shares of preferred stock with a par value of $0.001 per share. In connection with the closing of the IPO, all outstanding shares of the Company’s preferred stock converted into 17,797,026 shares of common stock which resulted in the reclassification of the carrying value of the preferred stock to common stock and additional paid-in capital. Additionally, the $33.0 million aggregate outstanding principal amount and $0.8 million accrued interest of the 2020 Notes converted into 2,561,484 shares of common stock at a conversion price of $13.20 per share.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of PresentationThe Company’s unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. Significant estimates and assumptions include reserves and write-downs related to inventories, the recoverability of long term assets, valuation of equity instruments and equity-linked instruments, valuation of common stock, stock-based compensation, valuation of the convertible preferred stock warrant liability and derivative liability, intangible assets, goodwill, debt and related features, deferred tax assets and related valuation allowances and impact of contingencies.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. The convertible preferred stock warrant liability and derivative liabilities are carried at fair value based on unobservable market inputs. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the term loan and convertible note approximates their fair value. The fair value of marketable debt securities is estimated using Level 2 inputs based on their quoted market values (Note 4).
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash, cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents balances with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance Corporation (“FDIC”) insured limits.
Deferred Offering Costs	Deferred Offering Costs Deferred offering costs, consisting of legal, accounting and other fees and costs relating to the Company’s planned IPO, are capitalized and recorded on the balance sheet. The deferred offering costs will be offset against the proceeds received upon the closing of the planned IPO. In the event that the Company’s plans for an IPO are
Foreign Currency Translation and Transaction Gains and Losses	Foreign Currency Translation and Transaction Gains and Losses The functional currencies of the Company’s wholly owned subsidiaries in the Cayman Islands and the Netherlands are the U.S. dollar. The functional currencies of the Company’s wholly owned subsidiaries in Switzerland, Germany, Australia, the United Kingdom, France and Hong Kong are the Swiss franc. The functional currency of the Company’s subsidiary in Italy is the Euro. Accordingly, asset and liability accounts of Switzerland, Germany, Australia, the United Kingdom, Italy and Hong Kong operations are translated into U.S. dollars using the current exchange rate in effect at the balance sheet date and equity accounts are translated into U.S. dollars using historical rates. The revenues and expenses are translated using the average exchange rates in effect during the period, and gains and losses from foreign currency translation adjustments are included as a component of accumulated other comprehensive income in the consolidated balance sheet. Foreign currency translation adjustments are recorded in other comprehensive income (loss) in the consolidated statements of operations and comprehensive loss and was less than $0.1 million and $0.1 million during the three months ended September 30, 2020 and 2019, respectively, and $0.3 million and $0.1 million during the nine months ended September 30, 2020 and 2019, respectively.
Net Loss per Share Attributable to Common Stockholders	Net Loss per Share Attributable to Common Stockholders Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, convertible preferred stock, stock options, common stock subject to repurchase related to early exercise of stock options, convertible preferred stock warrants and convertible note are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the convertible preferred stock is considered a participating security because it participates in dividends with common stock. The Company also considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities, because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of all series of convertible preferred stock and the holders of the shares issued upon early exercise of stock options subject to repurchase do not have a contractual obligation to share in the Company’s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.
Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted	Recently Adopted Accounting Pronouncements In August 2018, FASB issued ASU 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement . This ASU amends the disclosure requirement in ASC 820, Fair Value Measurement , by adding, changing or removing certain disclosures. This ASU applies to all entities that are required under this guidance to provide disclosure about recurring or nonrecurring fair value measurements. The amendments require new disclosures related to: changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period; range and weighted-average of significant unobservable inputs used to develop Level 3 fair value measurements. In addition, there are certain changes in disclosure requirements in the existing guidance. For all entities, this ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2018-13 as of January 1, 2020 and the adoption had no material impact on the Company’s consolidated financial statements. In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other: Simplifying the Test for Goodwill Impairment . The amendments eliminate Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. The amendments also eliminate the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. This ASU is effective for public business entities for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company adopted ASU 2017-04 as of January 1, 2020 and the adoption had no material impact on the Company’s consolidated financial statements. Recent Accounting Pronouncements Not Yet Adopted In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848) (“ASU 2020-04”). The amendments in ASU 2020-04 provide optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in ASU 2020-04 are effective for all entities as of March 12, 2020 through December 31, 2022. An entity may elect to apply the amendments for contract modifications by Topic or Industry Subtopic as of any date from the beginning an interim period that includes or is subsequent to March 12, 2020, or prospectively from the date that the financial statements are available to be issued. Once elected for a Topic or an Industry Subtopic, the amendments must be applied prospectively for all eligible contract modifications for that Topic or Industry Subtopic. The Company may elect to apply ASU 2020-04 as its contracts referenced in London Interbank Offered Rate (“LIBOR”) are impacted by reference rate reform. The Company is currently evaluating the impact of the adoption of this ASU on the Company’s consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40)—Accounting For Convertible Instruments and Contracts in an Entity's Own Equity (“ASU 2020-06”). ASU 2020-06 simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. ASU 2020-06 also simplifies the diluted net income per share calculation in certain areas. This ASU is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years, with early adoption permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently evaluating the impact of the adoption of this principle on the Company’s consolidated financial statements. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This ASU is effective for public business entities for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently evaluating the impact of the adoption of ASU 2019-12 on the Company’s consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses . This new guidance will require financial instruments to be measured at amortized cost, and trade accounts receivable to be presented at the net amount expected to be collected. The new model requires an entity to estimate credit losses based on historical information, current information and reasonable and supportable forecasts, including estimates of prepayments. In November 2019, the FASB issued ASU 2019-10, according to which, the new standard is effective for public business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies (“SRC”) as defined by the SEC, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. For all other entities , the new standard is effective for fiscal years beginning after December 15, 2022, and interim periods within that fiscal year. Early adoption is permitted. The Company is a SRC for fiscal year 2019 and 2020. The Company is currently evaluating the impact of the new standard on the Company’s consolidated financial statements.
Assets and Liabilities Measured at Fair Value	Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis – Financial assets and liabilities held by the Company measured at fair value on a recurring basis include money market funds, short-term marketable securities, convertible preferred stock warrant liability and derivative liabilities. Assets and Liabilities Measured and Recorded at Fair Value on a Nonrecurring Basis – The Company determines the fair value of long-lived assets held and used, such as intangible assets, by reference to independent appraisals, quoted market prices (e.g. an offer to purchase) and other factors. An impairment charge is recorded when the carrying value of the asset exceeds its fair value. As noted above, there have been no impairment charges recorded to date. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the term loan and convertible notes approximates their fair value and is classified as a Level 2 liability. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.
Derivative Liability	The Company valued the 2020 Notes derivative liability using the a “with and without” methodology. The “with and without” methodology involves valuing the convertible note on an as is basis and then valuing the 2020 Notes without each individual embedded derivative. The difference between the value of the 2020 Notes with the embedded derivatives and the value without each individual embedded derivative equals the fair value of that embedded derivative. In April 2020, the Company valued the embedded derivatives using a Monte Carlo Simulation (“MCS”). The first step of each simulation was to forecast the Company’s Series G-1 convertible preferred stock price through the expiration of the 2020 Notes. In order to estimate the future share price of the Series G-1 convertible preferred stock, The Company applied a “random walk” model based upon a Geometric Brownian Motion process with a constant drift.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following tables summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): September 30, 2020 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 10,133 $ — $ — $ 10,133 Cash equivalents 10,133 — — 10,133 Total financial assets $ 10,133 $ — $ — $ 10,133 Liabilities: Success fee derivative liability $ — $ — $ 1,856 $ 1,856 2020 Notes derivative liability — — — — Total financial liabilities $ — $ — $ 1,856 $ 1,856 December 31, 2019 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 6,318 $ — $ — $ 6,318 Commercial paper — 1,000 — 1,000 Cash equivalents 6,318 1,000 — 7,318 Corporate bonds — 7,105 — 7,105 Commercial paper — 6,475 — 6,475 Short-term marketable securities — 13,580 — 13,580 Total financial assets $ 6,318 $ 14,580 $ — $ 20,898 Liabilities: Preferred stock warrant liability $ — $ — $ — $ — Success fee derivative liability — — 1,165 1,165 Total financial liabilities $ — $ — $ 1,165 $ 1,165
Schedule of Assumptions Used in Determining Fair Value	The fair value of the Series C-1 convertible preferred stock warrants was determined using the following assumptions: December 31, 2019 Risk-free interest rate 1.6 % Remaining contractual life (in years) 0.1 Dividend yield 0 % Volatility 57.5 % The fair value of the 2020 Notes derivative liability was determined using the following assumptions: April 17 2020 Risk-free interest rate 0.2 % Current Series G-1 convertible preferred stock value per share $ 0.84 Series G-1 convertible preferred stock volatility 34.4 %
Schedule of Fair Value of Liabilities	The change in fair value of the convertible preferred stock warrant liability and derivative liabilities is summarized below (in thousands): Convertible Preferred Stock Warrant Liability Success Fee Derivative Liability 2020 Notes Derivative Liability Beginning fair value, January 1, 2019 $ 12 $ 642 $ — Change in fair value (12) 523 — Ending fair value, December 31, 2019 $ — $ 1,165 $ — Beginning fair value, January 1, 2020 — 1,165 — Fair value at inception — — 3,900 Change in fair value — 691 (3,900) Ending fair value, September 30, 2020 $ — $ 1,856 $ —

Balance Sheet Components (Table

Balance Sheet Components (Tables)	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Cash and Cash Equivalents	The Company’s cash and cash equivalents consist of the following (in thousands): September 30, December 31, 2020 2019 Cash $ 29,673 $ 7,449 Cash equivalents: Money market funds 10,133 6,318 Commercial paper — 1,000 Total cash and cash equivalents $ 39,806 $ 14,767
Schedule of Inventory	Inventory consists of the following (in thousands): September 30, December 31, 2020 2019 Raw materials $ 3,286 $ 1,950 Work in process 328 180 Finished goods 5,674 3,482 Total inventory $ 9,288 $ 5,612
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following (in thousands): September 30, December 31, 2020 2019 Prepaid expenses $ 453 $ 436 Prepaid insurance 146 12 VAT receivable 246 387 Other current assets 192 766 Total prepaid expenses and other current assets $ 1,037 $ 1,601
Schedule of Property and Equipment, Net	Property and equipment, net consist of the following (in thousands): September 30, December 31, 2020 2019 Machinery and equipment $ 1,317 $ 1,269 Computer equipment and software 947 848 Furniture and fixtures 228 168 Leasehold improvements 58 57 Construction in progress 270 — Total 2,820 2,342 Less: accumulated depreciation (1,656) (1,440) Property and equipment, net $ 1,164 $ 902
Schedule Intangible Assets	Intangible assets consist of the following (in thousands): September 30, 2020 Gross Carrying Value Accumulated Amortization Net Carrying Value Developed technology $ 1,658 $ (1,272) $ 386 Trademarks 191 (146) 45 Total intangible assets $ 1,849 $ (1,418) $ 431 December 31, 2019 Gross Carrying Value Accumulated Amortization Net Carrying Value Developed technology $ 1,658 $ (1,188) $ 470 Trademarks 191 (137) 54 Total intangible assets $ 1,849 $ (1,325) $ 524
Schedule of Future Amortization Expense	Future amortization expense is as follows as of September 30, 2020 (in thousands): 2020 (remaining three months) $ 31 2021 123 2022 123 2023 123 2024 31 Total amortization expense $ 431
Schedule of Accrued Liabilities	Accrued liabilities consist of the following (in thousands): September 30, December 31, 2020 2019 Accrued employee bonuses and commissions $ 2,070 $ 3,064 Accrued vacation 1,690 1,098 Other accrued personnel related expenses 510 705 Accrued professional fees 1,736 1,337 Accrued interest 793 1,708 Sales taxes, franchise tax and VAT 427 762 Liability for early exercise of stock options 679 304 Other 939 485 Total accrued liabilities $ 8,844 $ 9,463

Long Term Debt and Convertibl_2

Long Term Debt and Convertible Notes (Tables)	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	The Oxford Finance Loan as of September 30, 2020 and as of December 31, 2019, consists of the following (in thousands): September 30, December 31, 2020 2019 Term loan $ — $ 15,000 Less: debt issuance costs — (27) Less: deferred financing costs — (8) Term loan $ — $ 14,965 The CIBC Loan as of September 30, 2020, consists of the following (in thousands): September 30, 2020 Term loan $ 17,000 Less: debt issuance costs (237) Term loan $ 16,763 The 2020 Notes consist of the following (in thousands): September 30, 2020 Convertible notes $ 33,000 Less: debt discount (3,246) Convertible notes $ 29,754
Schedule of Contractual Maturities of Financing Obligations	As of September 30, 2020, the aggregate future payments under the CIBC Loan, Credit Agreement, and 2020 Notes (including interest payments) are as follows (in thousands): 2020 (remaining three months) $ 182 2021 723 2022 53,702 2023 — 2024 — 2025 539 Total 55,146 Less: unamortized debt discount (3,483) Less: interest (4,607) Term loan, convertible notes, and credit agreement $ 47,056

Leases, Lease Commitments and_2

Leases, Lease Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Schedule of Operating Lease Cost and Additional Information	Operating lease cost consists of the following (in thousands): Nine Months Ended Operating lease cost $ 1,322 Short-term lease cost 9 Variable lease cost 227 Total lease cost $ 1,558 The following table summarizes additional information related to the Company’s operating leases as of September 30, 2020 (in thousands, except weighted average data): Right of use asset $ 9,489 Weighted average remaining lease term (years) 4.37 Weighted average discount rate (percent) 6.1 The following table summarizes other supplemental information related to the Company’s operating leases (in thousands): Cash paid for amounts included in the measurement of lease liabilities included in cash flows used in operating activities $ 963 Right-of-use assets obtained in exchange for lease liabilities $ 3,882
Schedule of Maturity Analysis of Lease Liabilities	The following table summarizes a maturity analysis of the Company’s lease liabilities showing the aggregate lease payments as of September 30, 2020 (in thousands): 2020 (remaining 3 months) $ 522 2021 2,712 2022 2,069 2023 2,795 2024 2,589 2025 and beyond 1,007 Total minimum lease payments 11,694 Less: Amount of lease payments representing interest 1,517 Present value of future minimum lease payments $ 10,177 Less: Current lease liabilities $ 1,927 Long-term lease liabilities $ 8,250

Warrants for Convertible Pref_2

Warrants for Convertible Preferred Stock (Tables)	9 Months Ended
	Sep. 30, 2020
Warrants and Rights Note Disclosure [Abstract]
Schedule of Outstanding Convertible Preferred Stock Warrants	A summary of the outstanding convertible preferred stock warrants is as follows (in thousands, except per share and share amounts): December 31, 2019 Exercise Price Per share Shares Fair Value of Liability Expiration Date Series C-1 convertible preferred stock warrants $ 10.57 215,291 $ — February 9, 2020

Convertible Preferred Stock (Ta

Convertible Preferred Stock (Tables)	9 Months Ended
	Sep. 30, 2020
Temporary Equity Disclosure [Abstract]
Schedule of Convertible Preferred Stock	As of December 31, 2019, convertible preferred stock consists of the following (in thousands, except per share and share amounts): Series Number of Shares Authorized Number of Shares Issued and Outstanding Carrying Value (1) Liquidation Preference per Share Liquidation Value Series A-1 8,486,224 848,595 $ 8,135 $ 9.59 $ 8,138 Series B-1 24,224,676 2,422,444 23,130 10.57 25,605 Series C-1 39,422,980 3,726,974 37,306 10.57 39,395 Series D-1 9,400,000 939,979 10,268 11.00 10,340 Series E-1 9,230,768 923,049 11,896 13.00 12,000 Series F-1 37,878,787 3,787,878 49,800 13.20 50,000 Series G-1 49,342,376 4,934,231 64,804 13.20 65,132 Total 177,985,811 17,583,150 $ 205,339 $ 210,610 _______________ (1) Carrying values above are net of issuance costs. As of September 30, 2020, convertible preferred stock consists of the following (in thousands, except per share and share amounts): Series Number of Shares Authorized Number of Shares Issued and Outstanding Carrying Value (1) Liquidation Preference per Share Liquidation Value Series A-1 848,623 848,595 $ 8,135 $ 9.59 $ 8,138 Series B-1 2,422,468 2,422,444 23,130 10.57 25,605 Series C-1 3,942,298 3,940,850 39,566 10.57 41,655 Series D-1 940,000 939,979 10,268 11.00 10,340 Series E-1 923,077 923,049 11,896 13.00 12,000 Series F-1 3,787,879 3,787,878 49,800 13.20 50,000 Series G-1 10,009,996 4,934,231 64,804 13.20 65,132 Total 22,874,341 17,797,026 $ 207,599 $ 212,870 _______________ (1) Carrying values above are net of issuance costs.

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Schedule of Shares Reserved for Future Issuance	The Company has reserved shares of common stock for future issuances as follows: September 30, December 31, 2020 2019 Series A-1 convertible preferred stock outstanding 848,595 848,595 Series B-1 convertible preferred stock outstanding 2,422,444 2,422,444 Series C-1 convertible preferred stock outstanding 3,940,850 3,726,974 Series D-1 convertible preferred stock outstanding 939,979 939,979 Series E-1 convertible preferred stock outstanding 923,049 923,049 Series F-1 convertible preferred stock outstanding 3,787,878 3,787,878 Series G-1 convertible preferred stock outstanding 4,934,231 4,934,231 Warrants to purchase Series C-1 convertible preferred stock — 215,291 Convertible notes* 2,561,484 — Common stock options issued and outstanding 2,940,930 3,279,324 Common stock available for future grants 3,253,500 77,603 Total 26,552,940 21,155,368 _______________ * At September 30, 2020, the conversion of the 2020 Notes into convertible preferred stock was dependent on the outstanding loan balance including accrued interest and the per share conversion price (see Note 6). Upon closing the IPO, on October 5, 2020, the aggregate outstanding principal amount plus accrued interest under the 2020 Notes converted into 2,561,484 shares of common stock, which was used to determine the number of common stock issuable upon conversion of 2020 Notes.
Schedule of Summary of Stock Option Activity	A summary of stock option activity for the nine months ended September 30, 2020 is set forth below: Outstanding Options Shares Available for Grant Number of Shares Weighted Average Exercise Price Balance, January 1, 2020 77,603 3,279,324 $ 1.66 Additional shares reserved 4,553,378 — Options granted (1,416,271) 1,416,271 6.36 Options exercised (1,711,621) 1.55 Options canceled (1) 38,790 (43,044) 4.67 Balance, September 30, 2020 3,253,500 2,940,930 $ 3.94 ______________ (1) Canceled stock options issued under the Company’s 2000 Stock Plan were canceled after the 2010 Stock Plan was approved and are not included in the shares available for grant as they were not returned to the stock option pool.
Schedule of Options Vested and Expected to Vest	September 30, 2020 Number of Shares Weighted Average Exercise Price Weighted Average Contractual Life (in Years) Options vested 1,137,472 $ 1.79 5.86 Options vested and expected to vest 2,940,930 $ 3.94 8.16
Schedule of Total Stock-Based Compensation	Stock-based compensation expense is reflected in the statements of operations and comprehensive loss as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Cost of goods sold $ 37 $ 4 $ 67 $ 13 Research and development 63 13 96 44 Selling, general and administrative 418 55 723 140 Total $ 518 $ 72 $ 886 $ 197

Net Loss per Share Attributab_2

Net Loss per Share Attributable to Common Stockholders (Tables)	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss per Share	The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders which excludes shares which are legally outstanding, but subject to repurchase by the Company (in thousands, except share and per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Numerator Net loss attributable to common stockholders $ (3,860) $ (4,335) $ (22,934) $ (16,034) Denominator Weighted-average common stock outstanding 2,951,564 1,825,452 2,389,145 1,761,714 Less: weighted-average common shares subject to repurchase (136,766) (25,166) (168,411) (21,642) Weighted-average common shares used to compute basic and diluted net loss per share 2,814,798 1,800,286 2,220,734 1,740,072 Net loss per share attributable to common stockholders, basic and diluted $ (1.37) $ (2.41) $ (10.33) $ (9.21)
Schedule of Potentially Dilutive Securities Outstanding	The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company’s net loss, in common stock equivalent shares: As of September 30, 2020 2019 Convertible preferred stock 17,797,026 17,583,150 Convertible preferred stock warrants — 215,291 Options to purchase common stock 2,940,930 2,703,723 Unvested early exercised common stock options 381,387 175,331 Convertible notes* 2,561,484 — Total 23,680,827 20,677,495 _______________ * At September 30, 2020, the conversion of the 2020 Notes into convertible preferred stock was dependent on the outstanding loan balance including accrued interest and the per share conversion price (see Note 6). Upon closing the IPO, on October 5, 2020, the aggregate outstanding principal amount plus accrued interest under the 2020 Notes converted into 2,561,484 shares of common stock, which was used to determine the number of common stock issuable upon conversion of 2020 Notes.

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Schedule of Revenue by Geographic Area	The following table sets forth the Company’s revenue by geographic area (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Europe, Middle-East and Africa (“EMEA”) $ 4,440 $ 4,698 $ 9,703 $ 13,441 Asia Pacific 827 915 1,846 2,609 Other International — 86 39 197 United States 5,345 3,405 11,315 6,001 Total $ 10,612 $ 9,104 $ 22,903 $ 22,248
Schedule of Long-lived Assets by Geographic Area	The following table sets forth the Company’s long-lived assets by geographic area (in thousands): September 30, December 31, 2020 2019 United States $ 1,129 $ 852 EMEA 28 40 Asia Pacific 7 10 Total $ 1,164 $ 902

Formation and Business of the_2

Formation and Business of the Company (Details) - USD ($) $ / shares in Units, $ in Thousands	Oct. 05, 2020	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Subsidiary, Sale of Stock [Line Items]
Common stock, shares authorized (in shares)		200,000,000		240,000,000
Common stock, par value (in dollars per share)		$ 0.001		$ 0.001
Convertible preferred stock, shares authorized (in shares)		22,874,341		177,985,811
Accumulated deficit		$ 233,437		$ 210,503
Cash used in operating activities		23,371	$ 17,294
Cash and cash equivalents		$ 39,806	$ 15,730	$ 14,767
Subsequent Event
Subsidiary, Sale of Stock [Line Items]
Common stock, shares authorized (in shares)	200,000,000
Common stock, par value (in dollars per share)	$ 0.001
Convertible preferred stock, shares authorized (in shares)	10,000,000
Preferred stock, par value (in dollars per share)	$ 0.001
Subsequent Event | Common Stock
Subsidiary, Sale of Stock [Line Items]
Conversion of convertible securities (in shares)	17,797,026
IPO | Subsequent Event
Subsidiary, Sale of Stock [Line Items]
Shares issued in transaction (in shares)	11,500,000
Share price (in dollars per share)	$ 19
Proceeds from initial public offering	$ 218,500
Proceeds from initial public offering, net of issuance costs	$ 201,400
Over-Allotment Option | Subsequent Event
Subsidiary, Sale of Stock [Line Items]
Shares issued in transaction (in shares)	1,500,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) $ in Thousands	Sep. 22, 2020	Sep. 30, 2020USD ($)	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)	Sep. 30, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Dec. 31, 2019USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock split ratio	0.1
Cash on deposit with foreign banks		$ 5,000						$ 5,000		$ 5,200
Deferred offering costs		1,680						1,680		$ 1,563
Write-off of deferred offering costs								3,000
Other comprehensive loss, foreign currency translation adjustments		33	$ (34)	$ 282	$ 71	$ 73	$ (17)	281	$ 127
Foreign currency transaction gains and (losses)		(100)			200			$ 200	$ 400
Maximum
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other comprehensive loss, foreign currency translation adjustments		$ 100			$ 100

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Assets and Liabilities (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Assets:
Short-term marketable securities	$ 0
Success fee derivative liability
Liabilities:
Derivative liability	1,900,000	$ 1,200,000
Recurring Basis
Assets:
Cash equivalents	10,133,000	7,318,000
Short-term marketable securities		13,580,000
Total financial assets	10,133,000	20,898,000
Liabilities:
Preferred stock warrant liability		0
Total financial liabilities	1,856,000	1,165,000
Recurring Basis | Corporate bonds
Assets:
Short-term marketable securities		7,105,000
Recurring Basis | Commercial paper
Assets:
Short-term marketable securities		6,475,000
Recurring Basis | Success fee derivative liability
Liabilities:
Derivative liability	1,856,000	1,165,000
Recurring Basis | 2020 Notes derivative liability
Liabilities:
Derivative liability	0
Level 1 | Recurring Basis
Assets:
Cash equivalents	10,133,000	6,318,000
Short-term marketable securities		0
Total financial assets	10,133,000	6,318,000
Liabilities:
Preferred stock warrant liability		0
Total financial liabilities	0	0
Level 1 | Recurring Basis | Corporate bonds
Assets:
Short-term marketable securities		0
Level 1 | Recurring Basis | Commercial paper
Assets:
Short-term marketable securities		0
Level 1 | Recurring Basis | Success fee derivative liability
Liabilities:
Derivative liability	0	0
Level 1 | Recurring Basis | 2020 Notes derivative liability
Liabilities:
Derivative liability	0
Level 2 | Recurring Basis
Assets:
Cash equivalents	0	1,000,000
Short-term marketable securities		13,580,000
Total financial assets	0	14,580,000
Liabilities:
Preferred stock warrant liability		0
Total financial liabilities	0	0
Level 2 | Recurring Basis | Corporate bonds
Assets:
Short-term marketable securities		7,105,000
Level 2 | Recurring Basis | Commercial paper
Assets:
Short-term marketable securities		6,475,000
Level 2 | Recurring Basis | Success fee derivative liability
Liabilities:
Derivative liability	0	0
Level 2 | Recurring Basis | 2020 Notes derivative liability
Liabilities:
Derivative liability	0
Level 3 | Recurring Basis
Assets:
Cash equivalents	0	0
Short-term marketable securities		0
Total financial assets	0	0
Liabilities:
Preferred stock warrant liability		0
Total financial liabilities	1,856,000	1,165,000
Level 3 | Recurring Basis | Corporate bonds
Assets:
Short-term marketable securities		0
Level 3 | Recurring Basis | Commercial paper
Assets:
Short-term marketable securities		0
Level 3 | Recurring Basis | Success fee derivative liability
Liabilities:
Derivative liability	1,856,000	1,165,000
Level 3 | Recurring Basis | 2020 Notes derivative liability
Liabilities:
Derivative liability	0
Money market funds | Recurring Basis
Assets:
Cash equivalents	10,133,000	6,318,000
Money market funds | Level 1 | Recurring Basis
Assets:
Cash equivalents	10,133,000	6,318,000
Money market funds | Level 2 | Recurring Basis
Assets:
Cash equivalents	0	0
Money market funds | Level 3 | Recurring Basis
Assets:
Cash equivalents	$ 0	0
Commercial paper | Recurring Basis
Assets:
Cash equivalents		1,000,000
Commercial paper | Level 1 | Recurring Basis
Assets:
Cash equivalents		0
Commercial paper | Level 2 | Recurring Basis
Assets:
Cash equivalents		1,000,000
Commercial paper | Level 3 | Recurring Basis
Assets:
Cash equivalents		$ 0

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details)	Sep. 30, 2020USD ($)	Dec. 31, 2019USD ($)
Derivative [Line Items]
Marketable securities	$ 0
Success fee derivative liability
Derivative [Line Items]
Success Fee amount	$ 1,900,000	$ 1,200,000
Measurement Input, Probability Of Liquidity Event | Success fee derivative liability
Derivative [Line Items]
Derivative liability, measurement input	0.99	0.65

Fair Value Measurements - Valua

Fair Value Measurements - Valuation Assumptions (Details) - Valuation Technique, Option Pricing Model	Apr. 17, 2020$ / shares	Dec. 31, 2019
Risk-free interest rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible preferred stock warrants, measurement input		0.016
Remaining contractual life (in years)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible preferred stock warrants, measurement input		0.1
Dividend yield
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible preferred stock warrants, measurement input		0
Volatility
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible preferred stock warrants, measurement input		0.575
2020 Notes Derivative Liability | Risk-free interest rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability, measurement input	0.002
2020 Notes Derivative Liability | Current Series G-1 convertible preferred stock value per share
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability, measurement input	0.84
2020 Notes Derivative Liability | Volatility
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability, measurement input	0.344

Fair Value Measurements - Fai_2

Fair Value Measurements - Fair Value of Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019
Convertible Preferred Stock Warrant Liability
Convertible Preferred Stock Warrant Liability
Beginning fair value		$ 0	$ 12
Change in fair value		0	(12)
Ending fair value	$ 0	0	0
Success Fee Derivative Liability
Derivative Liability
Beginning fair value		1,165	642
Change in fair value		691	523
Ending fair value	1,856	1,856	1,165
2020 Notes Derivative Liability
Derivative Liability
Beginning fair value		0
Fair value at inception		3,900
Change in fair value	3,300	(3,900)
Ending fair value	$ 0	$ 0	$ 0

Balance Sheet Components - Cash

Balance Sheet Components - Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 29,673	$ 7,449
Cash equivalents:
Money market funds	10,133	6,318
Commercial paper	0	1,000
Total cash and cash equivalents	$ 39,806	$ 14,767	$ 15,730

Balance Sheet Components - Inve

Balance Sheet Components - Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 3,286	$ 1,950
Work in process	328	180
Finished goods	5,674	3,482
Total inventory	$ 9,288	$ 5,612

Balance Sheet Components - Prep

Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Prepaid expenses	$ 453	$ 436
Prepaid insurance	146	12
VAT receivable	246	387
Other current assets	192	766
Total prepaid expenses and other current assets	$ 1,037	$ 1,601

Balance Sheet Components - Prop

Balance Sheet Components - Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	$ 2,820	$ 2,342
Less: accumulated depreciation	(1,656)	(1,440)
Property and equipment, net	1,164	902
Machinery and equipment
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	1,317	1,269
Computer equipment and software
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	947	848
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	228	168
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	58	57
Construction in progress
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	$ 270	$ 0

Balance Sheet Components - Narr

Balance Sheet Components - Narrative (Details) - USD ($)	3 Months Ended				9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Depreciation expense	$ 100,000			$ 100,000	$ 300,000	$ 200,000
Goodwill	2,333,000				2,333,000		$ 2,333,000
Goodwill, accumulated impairment loss	0				0
Goodwill acquired					0	0
Goodwill disposed of					0	0
Goodwill, impairment loss	0	$ 0	$ 0
Amortization expense related to intangibles	$ 100,000			$ 100,000	$ 100,000	$ 100,000

Balance Sheet Components - Inta

Balance Sheet Components - Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 1,849	$ 1,849
Accumulated Amortization	(1,418)	(1,325)
Net Carrying Value	431	524
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	1,658	1,658
Accumulated Amortization	(1,272)	(1,188)
Net Carrying Value	386	470
Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	191	191
Accumulated Amortization	(146)	(137)
Net Carrying Value	$ 45	$ 54

Balance Sheet Components - Futu

Balance Sheet Components - Future Amortization Expense (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2020 (remaining three months)	$ 31
2021	123
2022	123
2023	123
2024	31
Net Carrying Value	$ 431	$ 524

Balance Sheet Components - Accr

Balance Sheet Components - Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued employee bonuses and commissions	$ 2,070	$ 3,064
Accrued vacation	510	705
Other accrued personnel related expenses	1,690	1,098
Accrued professional fees	1,736	1,337
Accrued interest	793	1,708
Sales taxes, franchise tax and VAT	427	762
Liability for early exercise of stock options	679	304
Other	939	485
Total accrued liabilities	$ 8,844	$ 9,463

Long Term Debt And Convertibl_3

Long Term Debt And Convertible Notes - Oxford Finance Loan Narrative (Details) - USD ($)

Oct. 05, 2020

Feb. 20, 2020

Aug. 28, 2014

May 31, 2018

Aug. 31, 2014

Sep. 30, 2020

Sep. 30, 2019

Sep. 30, 2020

Sep. 30, 2019

Dec. 31, 2014

Dec. 31, 2019

May 31, 2017

Debt Instrument [Line Items]

Interest expense on deferred financing and debt issuance costs, less than

$ 901,000

$ 22,000

Success fee derivative liability

Debt Instrument [Line Items]

Derivative liability

$ 1,900,000

1,900,000

$ 1,200,000

Medium-term Notes | Oxford Finance Loan

Debt Instrument [Line Items]

Debt instrument, face amount including accordion feature

$ 20,000,000

Proceeds from issuance of debt

$ 15,000,000

Accordion feature on face amount of debt

$ 5,000,000

Stated interest rate

8.96%

Debt term

5 years

Interest payments term

36 months

Principal and interest payments term

24 months

Final payment, percentage of loan amount due

8.50%

Incremental fee amount due at maturity

$ 100,000

Fee amount

$ 900,000

$ 800,000

$ 400,000

Effective interest rate

11.11%

Contingent fee amount, maximum

$ 2,500,000

Contingent fee amount

1,900,000

1,900,000

$ 1,900,000

Repayments on term loan obligations

17,300,000

Extinguishment of debt

15,000,000

Final payment on loan

1,300,000

Accrued interest

100,000

Loss on extinguishment of debt

$ 400,000

Interest expense on deferred financing and debt issuance costs, less than

0

$ 100,000

100,000

100,000

Interest expense

$ 0

$ 400,000

$ 400,000

$ 1,300,000

Medium-term Notes | Oxford Finance Loan | Subsequent Event

Debt Instrument [Line Items]

Payments of debt fees

$ 1,900,000

Medium-term Notes | Oxford Finance Loan | 18 Months After August 28, 2014

Debt Instrument [Line Items]

Contingent fee amount, percentage of loan

6.25%

Contingent fee amount, term

18 months

Medium-term Notes | Oxford Finance Loan | Between 18 Months and 3 Years After August 28, 2014

Debt Instrument [Line Items]

Contingent fee amount, percentage of loan

8.75%

Medium-term Notes | Oxford Finance Loan | After Third Anniversary of August 28, 2014

Debt Instrument [Line Items]

Contingent fee amount, percentage of loan

12.50%

Medium-term Notes | Oxford Finance Loan | Debt Instrument, Covenant, Scenario One

Debt Instrument [Line Items]

Stated interest rate

8.71%

Medium-term Notes | Oxford Finance Loan | Debt Instrument, Covenant, Scenario Two

Debt Instrument [Line Items]

Component of annual rate calculation, percentage in addition to LIBOR rate

6.86%

Medium-term Notes | Oxford Finance Loan | Minimum | Between 18 Months and 3 Years After August 28, 2014

Debt Instrument [Line Items]

Contingent fee amount, term

18 months

Medium-term Notes | Oxford Finance Loan | Maximum | Between 18 Months and 3 Years After August 28, 2014

Debt Instrument [Line Items]

Contingent fee amount, term

3 years

Medium-term Notes | Oxford Finance Loan | London Interbank Offered Rate (LIBOR) | Debt Instrument, Covenant, Scenario Two

Debt Instrument [Line Items]

Basis spread on variable rate

1.85%

Long Term Debt and Convertibl_4

Long Term Debt and Convertible Notes - Oxford Finance Loan Components of Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Term loan	$ 55,146
Less: deferred financing costs	(3,483)
Term loan, convertible notes, and credit agreement	47,056
Medium-term Notes | Oxford Finance Loan
Debt Instrument [Line Items]
Term loan	0	$ 15,000
Less: debt issuance costs	0	(27)
Less: deferred financing costs	0	(8)
Term loan, convertible notes, and credit agreement	$ 0	$ 14,965

Long Term Debt and Convertibl_5

Long Term Debt and Convertible Notes - CIBC Loan Narrative (Details) - USD ($)	Feb. 20, 2020	Apr. 30, 2020	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019
Debt Instrument [Line Items]
Payment of fees to lender and third parties				$ 162,000	$ 0
Amortization of debt discount and debt issuance costs				$ 901,000	$ 22,000
CIBC Agreement | Medium-term Notes
Debt Instrument [Line Items]
Debt instrument, face amount including accordion feature	$ 32,000,000
Debt term	5 years
Interest payments term	24 months
Principal and interest payments term	36 months
Interest period extension term	36 months
Interest-only period, training period of revenue requirement	3 months
Revenue threshold for interest period extension term option	$ 20,000,000
Fee amount		$ 200,000
Effective interest rate			5.16%	5.16%
Minimum percentage of revenue requirement, trailing period of revenue	3 months
Minimum percentage of revenue requirement	80.00%
Unrestricted cash requirement period	4 months
Payment of fees to lender and third parties	$ 300,000
Amortization of debt discount and debt issuance costs			$ 100,000	$ 100,000
Interest expense			$ 200,000	$ 500,000
CIBC Agreement | Medium-term Notes | Prime Rate
Debt Instrument [Line Items]
Basis spread on variable rate	1.00%
CIBC Agreement, Tranche A | Medium-term Notes
Debt Instrument [Line Items]
Proceeds from issuance of debt	$ 17,000,000
CIBC Agreement, Tranche B | Medium-term Notes
Debt Instrument [Line Items]
Accordion feature on face amount of debt	8,000,000
Trailing period of revenue		6 months
Revenue threshold for additional borrowing		$ 15,000,000
CIBC Agreement, Tranche C | Medium-term Notes
Debt Instrument [Line Items]
Accordion feature on face amount of debt	$ 7,000,000
Trailing period of revenue	6 months
Revenue threshold for additional borrowing	$ 20,000,000
CIBC Agreement, Tranche C | Medium-term Notes | Prime Rate
Debt Instrument [Line Items]
Basis spread on variable rate	1.50%
CIBC Agreement, Tranche B Or Tranche C | Medium-term Notes
Debt Instrument [Line Items]
Structuring fee percentage		1.00%

Long Term Debt and Convertibl_6

Long Term Debt and Convertible Notes - CIBC Loan Components Of Debt (Details) $ in Thousands	Sep. 30, 2020USD ($)
Debt Instrument [Line Items]
Term loan	$ 55,146
Less: deferred financing costs	(3,483)
Outstanding loan amount	47,056
CIBC Agreement | Medium-term Notes
Debt Instrument [Line Items]
Term loan	17,000
Less: deferred financing costs	(237)
Outstanding loan amount	$ 16,763

Long Term Debt and Convertibl_7

Long Term Debt and Convertible Notes - Credit Agreement and Paycheck Protection Program Narrative (Details)	Apr. 16, 2020USD ($)	May 31, 2020USD ($)	Apr. 30, 2020USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Apr. 30, 2020CHF (SFr)
Debt Instrument [Line Items]
Proceeds from PPP				$ 2,666,000	$ 0
Paycheck Protection Program, CARES Act
Debt Instrument [Line Items]
Proceeds from PPP	$ 2,700,000
Line of Credit | COVID-19 Credit Agreement | Pulmonx International Sarl
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 500,000			SFr 500,000
Proceeds from Credit Agreement		$ 500,000
Debt term			60 months
Repayments on credit agreement				$ 0

Long Term Debt and Convertibl_8

Long Term Debt and Convertible Notes - Convertible Notes Narrative (Details) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Apr. 30, 2020	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019
Debt Instrument [Line Items]
Proceeds from convertible debt			$ 32,950,000	$ 6,000,000
Embedded derivative liability	$ 3,900,000	$ 0	0
Debt issuance costs			162,000	0
Amortization of debt discount and debt issuance costs			901,000	$ 22,000
Accrued interest		4,607,000	4,607,000
2020 Notes Derivative Liability
Debt Instrument [Line Items]
Increase (decrease) in fair value of derivative		3,300,000	(3,900,000)
Convertible Debt | 2020 Notes Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity	66,000,000
Remaining borrowing capacity		33,000,000	33,000,000
Threshold stock proceeds for conversion	30,000,000
Debt issuance costs	100,000
Amortization of debt discount and debt issuance costs	$ 100,000
Interest expense		900,000	1,600,000
Accrued interest		$ 800,000	$ 800,000
Effective interest rate		12.33%	12.33%
Convertible Debt | 2020 Notes Agreement | Prime Rate
Debt Instrument [Line Items]
Basis spread on variable rate	2.00%
Convertible Debt | 2020 Notes Agreement | Debt Instrument, Convertible, Conversion Feature, Scenario Two
Debt Instrument [Line Items]
Conversion price per share (in dollars per share)	$ 13.20
Convertible Debt | 2020 Notes Agreement | Debt Instrument, Convertible, Conversion Feature, Scenario Two | Series G-1
Debt Instrument [Line Items]
Conversion price per share (in dollars per share)	$ 13.20
Convertible Debt | 2020 Notes Agreement | Debt Instrument, Convertible, Conversion Feature, Non-Qualified Financing Scenario
Debt Instrument [Line Items]
Threshold stock proceeds from non-significant holders for conversion	$ 10,000,000
Threshold of debt for Significant Holder	$ 20,000,000
Convertible Debt | 2020 Notes Agreement | Debt Instrument, Conversion Feature, Non-Qualified Financing, Scenario One
Debt Instrument [Line Items]
Percentage of stock price	75.00%
Convertible Debt | 2020 Notes Agreement | Debt Instrument, Convertible, Conversion Feature, Non-Qualified Financing, Scenario Two
Debt Instrument [Line Items]
Percentage of stock price	75.00%
Convertible Debt | 2020 Notes Agreement | Debt Instrument, Convertible, Conversion Feature, Non-Qualified Financing, Scenario Two | Series G-1
Debt Instrument [Line Items]
Conversion price per share (in dollars per share)	$ 13.20
Convertible Debt | 2020 Notes Agreement | Debt Instrument, Convertible, Conversion Feature, Qualified IPO Scenario
Debt Instrument [Line Items]
Stock proceeds threshold for conversion	$ 30,000,000
Convertible Debt | 2020 Notes Agreement | Debt Instrument, Convertible, Conversion Feature, Qualified IPO, Scenario Two
Debt Instrument [Line Items]
Conversion price per share (in dollars per share)	$ 13.20
Convertible Debt | 2020 Notes Agreement | Debt Instrument, Convertible, Conversion Feature, Non-Qualified IPO, Scenario One
Debt Instrument [Line Items]
Percentage of stock price	75.00%
Convertible Debt | 2020 Notes Agreement | Debt Instrument, Convertible, Conversion Feature, Non-Qualified IPO, Scenario Two
Debt Instrument [Line Items]
Percentage of stock price	75.00%
Convertible Debt | 2020 Notes Agreement | Debt Instrument, Convertible, Conversion Feature, Non-Qualified IPO, Scenario Two | Series G-1
Debt Instrument [Line Items]
Conversion price per share (in dollars per share)	$ 13.20
Convertible Debt | 2020 Notes Agreement | Debt Instrument, Convertible, Conversion Feature, Default Scenario
Debt Instrument [Line Items]
Percentage of stock price	75.00%
Convertible Debt | 2020 Notes Agreement | Debt Covenant, Eighteen Months After Initial Closing | Debt Instrument, Convertible, Conversion Feature, Scenario One
Debt Instrument [Line Items]
Percentage of stock price	85.00%
Convertible Debt | 2020 Notes Agreement | Debt Covenant, Eighteen Months After Initial Closing | Debt Instrument, Convertible, Conversion Feature, Qualified IPO, Scenario One
Debt Instrument [Line Items]
Percentage of stock price	85.00%
Convertible Debt | 2020 Notes Agreement | Debt Covenant, Eighteen Months After Initial Closing, Thereafter | Debt Instrument, Convertible, Conversion Feature, Scenario One
Debt Instrument [Line Items]
Percentage of stock price	80.00%
Convertible Debt | 2020 Notes Agreement | Debt Covenant, Eighteen Months After Initial Closing, Thereafter | Debt Instrument, Convertible, Conversion Feature, Qualified IPO, Scenario Two
Debt Instrument [Line Items]
Percentage of stock price	80.00%
Convertible Debt | 2020 Notes Agreement, Tranche One
Debt Instrument [Line Items]
Proceeds from convertible debt	$ 33,000,000
Convertible Debt | 2020 Notes Agreement Over Allotment Option
Debt Instrument [Line Items]
Maximum draw amount	5,000,000
Convertible Debt | 2020 Notes Agreement, Tranche Two | Maximum
Debt Instrument [Line Items]
Remaining borrowing capacity	$ 33,000,000

Long Term Debt and Convertibl_9

Long Term Debt and Convertible Notes - Convertible Notes Components of Debt (Details) $ in Thousands	Sep. 30, 2020USD ($)
Debt Instrument [Line Items]
Term loan	$ 55,146
Outstanding loan amount	47,056
2020 Notes Agreement | Convertible Debt
Debt Instrument [Line Items]
Term loan	33,000
Less: deferred financing costs	(3,246)
Outstanding loan amount	$ 29,754

Long Term Debt and Convertib_10

Long Term Debt and Convertible Notes - Contractual Maturities of Financing Obligations (Details) $ in Thousands	Sep. 30, 2020USD ($)
Long-term Debt, Fiscal Year Maturity [Abstract]
2020 (remaining three months)	$ 182
2021	723
2022	53,702
2023	0
2024	0
2025	539
Total	55,146
Less: unamortized debt discount	(3,483)
Less: interest	(4,607)
Outstanding loan amount	$ 47,056

Revenue Recognition (Details)

Revenue Recognition (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Deferred revenue	$ 0.1	$ 0.2	$ 0.1
Revenue recognized	$ 0.2	$ 0.1

Leases, Lease Commitments and_3

Leases, Lease Commitments and Contingencies - Narrative (Details) $ in Millions	1 Months Ended			12 Months Ended
	Sep. 30, 2020USD ($)lease	Aug. 31, 2020USD ($)	Apr. 30, 2020	Dec. 31, 2013
Lessee, Lease, Description [Line Items]
Lease renewal term		5 years
Monthly base rent		$ 0.1
Annual increase rate		3.50%
Tenant improvement allowance, receivable upon lease renewal		$ 0.2
Option to terminate, notice period				12 months
Sublease term	4 years		3 years
Sublease, period for option to terminate			18 months
Sublease monthly rent	$ 0.1
Sublease renewal term	12 months
Number of vehicle leases | lease	2
Office Facilities
Lessee, Lease, Description [Line Items]
Lease term				5 years
Minimum | Vehicles
Lessee, Lease, Description [Line Items]
Lease term	2 years
Maximum | Vehicles
Lessee, Lease, Description [Line Items]
Lease term	4 years

Leases, Lease Commitments and_4

Leases, Lease Commitments and Contingencies - Lease Cost (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
Leases [Abstract]
Operating lease cost	$ 1,322
Short-term lease cost	9
Variable lease cost	227
Total lease cost	$ 1,558

Leases, Lease Commitments and_5

Leases, Lease Commitments and Contingencies - Maturity Analysis of Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2020 (remaining 3 months)	$ 522
2021	2,712
2022	2,069
2023	2,795
2024	2,589
2025 and beyond	1,007
Total minimum lease payments	11,694
Less: Amount of lease payments representing interest	1,517
Present value of future minimum lease payments	10,177
Less: Current lease liabilities	1,927	$ 446
Long-term lease liabilities	$ 8,250	$ 6,403

Leases, Lease Commitments and_6

Leases, Lease Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Leases [Abstract]
Right of use asset	$ 9,489	$ 6,561
Weighted average remaining lease term (years)	4 years 4 months 13 days
Weighted average discount rate (percent)	6.10%

Leases, Lease Commitments and_7

Leases, Lease Commitments and Contingencies - Other Supplemental Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities included in cash flows used in operating activities	$ 963
Right-of-use assets obtained in exchange for lease liabilities	$ 3,882	$ 0

Warrants for Convertible Pref_3

Warrants for Convertible Preferred Stock - Outstanding Convertible Preferred Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Warrants and Rights Note Disclosure [Abstract]
Exercise Price Per share (in dollars per share)		$ 10,570
Warrants outstanding (in shares)	0	215,291,000
Fair Value of Liability		$ 0

Warrants for Convertible Pref_4

Warrants for Convertible Preferred Stock - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	2 Months Ended		3 Months Ended
	Apr. 30, 2019	Feb. 29, 2020	Feb. 28, 2020	Mar. 31, 2020	Jun. 30, 2019	Sep. 30, 2020	Dec. 31, 2019
Warrants and Rights Note Disclosure [Abstract]
Issuance of convertible preferred stock (in shares)	1,903,935	213,876		213,876	4,934,231
Convertible securities, exercise price per share (in dollars per share)			$ 10.57
Proceeds from stock issued	$ 40,000		$ 2,300	$ 2,260	$ 64,875
Warrants expired, unexercised (in shares)			1,415
Warrants outstanding (in shares)						0	215,291,000

Convertible Preferred Stock - N

Convertible Preferred Stock - Narrative (Details) $ / shares in Units, $ in Thousands	1 Months Ended	2 Months Ended		3 Months Ended		9 Months Ended
	Apr. 30, 2019USD ($)$ / sharesshares	Feb. 29, 2020shares	Feb. 28, 2020USD ($)	Mar. 31, 2020USD ($)shares	Jun. 30, 2019USD ($)shares	Sep. 30, 2020USD ($)votemember$ / sharesshares	Sep. 30, 2019USD ($)	Dec. 31, 2019USD ($)$ / sharesshares
Class of Stock [Line Items]
Convertible preferred stock, shares authorized (in shares) | shares						22,874,341		177,985,811
Issuance of convertible preferred stock (in shares) | shares	1,903,935	213,876		213,876	4,934,231
Shares issued, price per share (in dollars per share)	$ 13.20
Proceeds from stock issued | $	$ 40,000		$ 2,300	$ 2,260	$ 64,875
Amount of debt converted | $	$ 25,100					$ 0	$ 25,133
Liquidation value | $						$ 212,870		$ 210,610
Percentage of voting power prior to transaction						50.00%
Number of votes for each share of common stock held | vote						1
Number of members of Board of Directors | member						8
Minimum aggregate cash proceeds from sale of stock | $						$ 30,000
Series A-1
Class of Stock [Line Items]
Convertible preferred stock, shares authorized (in shares) | shares						848,623		8,486,224
Dividend rate (in dollars per share)						$ 0.7672
Liquidation preference (in dollars per share)						$ 9.59		$ 9.59
Liquidation value | $						$ 8,138		$ 8,138
Liquidation preference, aggregate amount received per share (in dollars per share)						$ 28.77
Minimum shares outstanding for voting power (in shares) | shares						50,000
Number of Board of Director members entitled to be elected | member						1
Series B-1
Class of Stock [Line Items]
Convertible preferred stock, shares authorized (in shares) | shares						2,422,468		24,224,676
Dividend rate (in dollars per share)						$ 0.8456
Liquidation preference (in dollars per share)						$ 10.57		$ 10.57
Liquidation value | $						$ 25,605		$ 25,605
Liquidation preference, aggregate amount received per share (in dollars per share)						$ 31.71
Minimum shares outstanding for voting power (in shares) | shares						50,000
Number of Board of Director members entitled to be elected | member						2
Series C-1
Class of Stock [Line Items]
Convertible preferred stock, shares authorized (in shares) | shares						3,942,298		39,422,980
Dividend rate (in dollars per share)						$ 0.8456
Liquidation preference (in dollars per share)						$ 10.57		$ 10.57
Liquidation value | $						$ 41,655		$ 39,395
Liquidation preference, aggregate amount received per share (in dollars per share)						$ 31.71
Minimum shares outstanding for voting power (in shares) | shares						50,000
Number of Board of Director members entitled to be elected | member						2
Series D-1
Class of Stock [Line Items]
Convertible preferred stock, shares authorized (in shares) | shares						940,000		9,400,000
Dividend rate (in dollars per share)						$ 0.88
Liquidation preference (in dollars per share)						$ 11		$ 11
Liquidation value | $						$ 10,340		$ 10,340
Liquidation preference, aggregate amount received per share (in dollars per share)						$ 33
Series E-1
Class of Stock [Line Items]
Convertible preferred stock, shares authorized (in shares) | shares						923,077		9,230,768
Dividend rate (in dollars per share)						$ 1.04
Liquidation preference (in dollars per share)						$ 13		$ 13
Liquidation value | $						$ 12,000		$ 12,000
Liquidation preference, aggregate amount received per share (in dollars per share)						$ 39
Series F-1
Class of Stock [Line Items]
Convertible preferred stock, shares authorized (in shares) | shares						3,787,879		37,878,787
Dividend rate (in dollars per share)						$ 1.056
Liquidation preference (in dollars per share)						$ 13.20		$ 13.20
Period to determine Additional Preference						1 year
Liquidation value | $						$ 50,000		$ 50,000
Liquidation preference, aggregate amount received per share (in dollars per share)						$ 39.60
Series F-1 | Equity to or greater than $250.0 million, but less than $300.0 million
Class of Stock [Line Items]
Additional preference per share (in dollars per share)						3.30
Series F-1 | Equity to or greater than $300.0 million but less than $350.0 million
Class of Stock [Line Items]
Liquidation preference (in dollars per share)						5
Series F-1 | Equal to or greater than $350.0 million
Class of Stock [Line Items]
Liquidation preference (in dollars per share)						$ 6.60
Liquidation value | $						$ 350,000
Series F-1 | Minimum | Equity to or greater than $250.0 million, but less than $300.0 million
Class of Stock [Line Items]
Additional preference, liquidation transaction threshold | $						250,000
Series F-1 | Minimum | Equity to or greater than $300.0 million but less than $350.0 million
Class of Stock [Line Items]
Liquidation value | $						300,000
Series F-1 | Maximum | Equity to or greater than $250.0 million, but less than $300.0 million
Class of Stock [Line Items]
Liquidation value | $						300,000
Series F-1 | Maximum | Equity to or greater than $300.0 million but less than $350.0 million
Class of Stock [Line Items]
Liquidation value | $						$ 350,000
Series G-1
Class of Stock [Line Items]
Convertible preferred stock, shares authorized (in shares) | shares						10,009,996		49,342,376
Issuance of convertible preferred stock (in shares) | shares	3,030,296
Dividend rate (in dollars per share)						$ 1.056
Liquidation preference (in dollars per share)						$ 13.20		$ 13.20
Liquidation value | $						$ 65,132		$ 65,132
Liquidation preference, aggregate amount received per share (in dollars per share)						$ 39.60
Minimum shares outstanding for voting power (in shares) | shares						50,000
Number of Board of Director members entitled to be elected | member						1
Conversion ratio						1.15

Convertible Preferred Stock - S

Convertible Preferred Stock - Schedule of Convertible Preferred Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018
Class of Stock [Line Items]
Number of Shares Authorized (in shares)	22,874,341			177,985,811
Number of Shares Issued (in shares)	17,797,026			17,583,150
Number of Shares Outstanding (in shares)	17,797,026	17,797,026	17,797,026	17,583,150	17,583,150	17,583,150	12,648,919	12,648,919
Convertible preferred stock, $0.001 par value, 22,874,341 and 177,985,811 shares authorized as of September 30, 2020 and December 31, 2019; 17,797,026 and 17,583,150 shares issued and outstanding as of September 30, 2020 and December 31, 2019; liquidation value of $212,870 and $210,610 as of September 30, 2020 and December 31, 2019 (Note 11)	$ 207,599	$ 207,599	$ 207,599	$ 205,339	$ 205,339	$ 205,339	$ 140,464	$ 140,535
Liquidation Value	$ 212,870			$ 210,610
Series A-1
Class of Stock [Line Items]
Number of Shares Authorized (in shares)	848,623			8,486,224
Number of Shares Issued (in shares)	848,595			848,595
Number of Shares Outstanding (in shares)	848,595			848,595
Convertible preferred stock, $0.001 par value, 22,874,341 and 177,985,811 shares authorized as of September 30, 2020 and December 31, 2019; 17,797,026 and 17,583,150 shares issued and outstanding as of September 30, 2020 and December 31, 2019; liquidation value of $212,870 and $210,610 as of September 30, 2020 and December 31, 2019 (Note 11)	$ 8,135			$ 8,135
Liquidation Preference per Share (in dollars per share)	$ 9.59			$ 9.59
Liquidation Value	$ 8,138			$ 8,138
Series B-1
Class of Stock [Line Items]
Number of Shares Authorized (in shares)	2,422,468			24,224,676
Number of Shares Issued (in shares)	2,422,444			2,422,444
Number of Shares Outstanding (in shares)	2,422,444			2,422,444
Convertible preferred stock, $0.001 par value, 22,874,341 and 177,985,811 shares authorized as of September 30, 2020 and December 31, 2019; 17,797,026 and 17,583,150 shares issued and outstanding as of September 30, 2020 and December 31, 2019; liquidation value of $212,870 and $210,610 as of September 30, 2020 and December 31, 2019 (Note 11)	$ 23,130			$ 23,130
Liquidation Preference per Share (in dollars per share)	$ 10.57			$ 10.57
Liquidation Value	$ 25,605			$ 25,605
Series C-1
Class of Stock [Line Items]
Number of Shares Authorized (in shares)	3,942,298			39,422,980
Number of Shares Issued (in shares)	3,940,850			3,726,974
Number of Shares Outstanding (in shares)	3,940,850			3,726,974
Convertible preferred stock, $0.001 par value, 22,874,341 and 177,985,811 shares authorized as of September 30, 2020 and December 31, 2019; 17,797,026 and 17,583,150 shares issued and outstanding as of September 30, 2020 and December 31, 2019; liquidation value of $212,870 and $210,610 as of September 30, 2020 and December 31, 2019 (Note 11)	$ 39,566			$ 37,306
Liquidation Preference per Share (in dollars per share)	$ 10.57			$ 10.57
Liquidation Value	$ 41,655			$ 39,395
Series D-1
Class of Stock [Line Items]
Number of Shares Authorized (in shares)	940,000			9,400,000
Number of Shares Issued (in shares)	939,979			939,979
Number of Shares Outstanding (in shares)	939,979			939,979
Convertible preferred stock, $0.001 par value, 22,874,341 and 177,985,811 shares authorized as of September 30, 2020 and December 31, 2019; 17,797,026 and 17,583,150 shares issued and outstanding as of September 30, 2020 and December 31, 2019; liquidation value of $212,870 and $210,610 as of September 30, 2020 and December 31, 2019 (Note 11)	$ 10,268			$ 10,268
Liquidation Preference per Share (in dollars per share)	$ 11			$ 11
Liquidation Value	$ 10,340			$ 10,340
Series E-1
Class of Stock [Line Items]
Number of Shares Authorized (in shares)	923,077			9,230,768
Number of Shares Issued (in shares)	923,049			923,049
Number of Shares Outstanding (in shares)	923,049			923,049
Convertible preferred stock, $0.001 par value, 22,874,341 and 177,985,811 shares authorized as of September 30, 2020 and December 31, 2019; 17,797,026 and 17,583,150 shares issued and outstanding as of September 30, 2020 and December 31, 2019; liquidation value of $212,870 and $210,610 as of September 30, 2020 and December 31, 2019 (Note 11)	$ 11,896			$ 11,896
Liquidation Preference per Share (in dollars per share)	$ 13			$ 13
Liquidation Value	$ 12,000			$ 12,000
Series F-1
Class of Stock [Line Items]
Number of Shares Authorized (in shares)	3,787,879			37,878,787
Number of Shares Issued (in shares)	3,787,878			3,787,878
Number of Shares Outstanding (in shares)	3,787,878			3,787,878
Convertible preferred stock, $0.001 par value, 22,874,341 and 177,985,811 shares authorized as of September 30, 2020 and December 31, 2019; 17,797,026 and 17,583,150 shares issued and outstanding as of September 30, 2020 and December 31, 2019; liquidation value of $212,870 and $210,610 as of September 30, 2020 and December 31, 2019 (Note 11)	$ 49,800			$ 49,800
Liquidation Preference per Share (in dollars per share)	$ 13.20			$ 13.20
Liquidation Value	$ 50,000			$ 50,000
Series G-1
Class of Stock [Line Items]
Number of Shares Authorized (in shares)	10,009,996			49,342,376
Number of Shares Issued (in shares)	4,934,231			4,934,231
Number of Shares Outstanding (in shares)	4,934,231			4,934,231
Convertible preferred stock, $0.001 par value, 22,874,341 and 177,985,811 shares authorized as of September 30, 2020 and December 31, 2019; 17,797,026 and 17,583,150 shares issued and outstanding as of September 30, 2020 and December 31, 2019; liquidation value of $212,870 and $210,610 as of September 30, 2020 and December 31, 2019 (Note 11)	$ 64,804			$ 64,804
Liquidation Preference per Share (in dollars per share)	$ 13.20			$ 13.20
Liquidation Value	$ 65,132			$ 65,132

Stockholders' Deficit - Narrati

Stockholders' Deficit - Narrative (Details)	9 Months Ended		12 Months Ended
	Sep. 30, 2020USD ($)vote$ / sharesshares	Sep. 30, 2019USD ($)shares	Dec. 31, 2019USD ($)shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized (in shares) | shares	200,000,000		240,000,000
Dividends declared	$ 0
Number of votes for each share of common stock held | vote	1
Stock retired during period (shares) | shares		414
Weighted average exercise price (in dollars per share) | $ / shares	$ 3.94
Options outstanding, aggregate intrinsic value	$ 44,300,000
Options exercisable, aggregate intrinsic value	44,300,000
Options vested and expenses to vest, intrinsic value	44,300,000
Common stock, shares repurchased, less than (in shares)	$ 100,000	$ 100,000
Repurchase of early exercised common stock options (in shares) | shares	10,000	812
Aggregate exercise price of shares subject to repurchase	$ 700,000		$ 300,000
Unrecognized compensation costs	$ 14,300,000
Options to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Shares subject to repurchase (in shares) | shares	381,387		199,810
Weighted-average period for recognition of compensation costs	2 years 4 months 28 days

Stockholders' Deficit - Shares

Stockholders' Deficit - Shares Reserved for Future Issuance (Details) - shares	Oct. 05, 2020	Sep. 30, 2020	Dec. 31, 2019
Class of Stock [Line Items]
Shares reserved for future issuance (in shares)		26,552,940	21,155,368
2020 Notes Agreement | Convertible Debt | Subsequent Event
Class of Stock [Line Items]
Shares issued upon conversion of debt (in shares)	2,561,484
Common stock options issued and outstanding
Class of Stock [Line Items]
Shares reserved for future issuance (in shares)		2,940,930	3,279,324
Common stock available for future grants
Class of Stock [Line Items]
Shares reserved for future issuance (in shares)		3,253,500	77,603
Warrants to purchase Series C-1 convertible preferred stock
Class of Stock [Line Items]
Shares reserved for future issuance (in shares)		0	215,291
Convertible Debt
Class of Stock [Line Items]
Shares reserved for future issuance (in shares)		2,561,484	0
Series A-1
Class of Stock [Line Items]
Shares reserved for future issuance (in shares)		848,595	848,595
Series B-1
Class of Stock [Line Items]
Shares reserved for future issuance (in shares)		2,422,444	2,422,444
Series C-1
Class of Stock [Line Items]
Shares reserved for future issuance (in shares)		3,940,850	3,726,974
Series D-1
Class of Stock [Line Items]
Shares reserved for future issuance (in shares)		939,979	939,979
Series E-1
Class of Stock [Line Items]
Shares reserved for future issuance (in shares)		923,049	923,049
Series F-1
Class of Stock [Line Items]
Shares reserved for future issuance (in shares)		3,787,878	3,787,878
Series G-1
Class of Stock [Line Items]
Shares reserved for future issuance (in shares)		4,934,231	4,934,231

Stockholders' Deficit - Stock O

Stockholders' Deficit - Stock Option Activity (Details)	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Shares Available for Grant
Options granted (in shares)	(1,416,271)
Options canceled (in shares)	43,044
Number of Shares
Balance, beginning of period (in shares)	3,279,324
Options granted (in shares)	1,416,271
Options exercised (in shares)	(1,711,621)
Options canceled (in shares)	(43,044)
Balance, end of period (in shares)	2,940,930
Weighted Average Exercise Price
Balance, beginning of period (in dollars per share) | $ / shares	$ 1.66
Options granted (in dollars per share) | $ / shares	6.36
Options exercised (in dollars per share) | $ / shares	1.55
Options canceled (in dollars per share) | $ / shares	4.67
Balance, end of period (in dollars per share) | $ / shares	$ 3.94
2000 Stock Plan
Shares Available for Grant
Options canceled (in shares)	38,790
Number of Shares
Options canceled (in shares)	(38,790)
Options to purchase common stock
Shares Available for Grant
Balance, beginning of period (in shares)	77,603
Additional shares reserved (in shares)	4,553,378
Balance, end of period (in shares)	3,253,500

Stockholders' Deficit - Options

Stockholders' Deficit - Options Vested and Expected to Vest (Details)	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Number of Shares
Options vested (in shares) | shares	1,137,472
Options vested and expected to vest (in shares) | shares	2,940,930
Weighted Average Exercise Price
Options vested (in dollars per share) | $ / shares	$ 1,790
Options vested and expected to vest (in dollars per share) | $ / shares	$ 3.94
Weighted Average Contractual Life (in Years)
Options vested	5 years 10 months 9 days
Options vested and expected to vest	8 years 1 month 28 days

Stockholders' Deficit - Total S

Stockholders' Deficit - Total Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 518	$ 72	$ 886	$ 197
Cost of goods sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	37	4	67	13
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	63	13	96	44
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 418	$ 55	$ 723	$ 140

Net Loss per Share Attributab_3

Net Loss per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Numerator
Net loss attributable to common stockholders	$ (3,860)	$ (4,335)	$ (22,934)	$ (16,034)
Denominator
Weighted-average common stock outstanding (in shares)	2,951,564	1,825,452	2,389,145	1,761,714
Less: weighted-average common shares subject to repurchase (in shares)	(136,766)	(25,166)	(168,411)	(21,642)
Weighted-average shares used in computing net loss per share attributable to common stockholder, basic and diluted (in shares)	2,814,798	1,800,286	2,220,734	1,740,072
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (1.37)	$ (2.41)	$ (10.33)	$ (9.21)

Net Loss per Share Attributab_4

Net Loss per Share Attributable to Common Stockholders - Excluded Potentially Dilutive Securities Outstanding (Details) - shares	Oct. 05, 2020	Sep. 30, 2020	Sep. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)		23,680,827	20,677,495
2020 Notes Agreement | Convertible Debt | Subsequent Event
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares issued upon conversion of debt (in shares)	2,561,484
Convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)		17,797,026	17,583,150
Convertible preferred stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)		0	215,291
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)		2,940,930	2,703,723
Unvested early exercised common stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)		381,387	175,331
Convertible notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)		2,561,484	0

Segment Information - Narrative

Segment Information - Narrative (Details)	9 Months Ended
	Sep. 30, 2020segment
Segment Reporting [Abstract]
Number of reportable segments	1
Number of operating segments	1

Segment Information - Revenue b

Segment Information - Revenue by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 10,612	$ 9,104	$ 22,903	$ 22,248
Europe, Middle-East and Africa (“EMEA”)
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	4,440	4,698	9,703	13,441
Asia Pacific
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	827	915	1,846	2,609
Other International
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	0	86	39	197
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 5,345	$ 3,405	$ 11,315	$ 6,001

Segment Information - Long-Live

Segment Information - Long-Lived Assets by Geographical Area (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 1,164	$ 902
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	1,129	852
Europe, Middle-East and Africa (“EMEA”)
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	28	40
Asia Pacific
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 7	$ 10

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Oct. 05, 2020	Sep. 30, 2020	Dec. 31, 2019
Subsequent Event [Line Items]
Outstanding loan amount		$ 47,056,000
Accrued interest		4,607,000
Subsequent Event | Common Stock
Subsequent Event [Line Items]
Conversion of convertible securities (in shares)	17,797,026
Subsequent Event | IPO
Subsequent Event [Line Items]
Shares issued in transaction (in shares)	11,500,000
Share price (in dollars per share)	$ 19
Proceeds from initial public offering, net of issuance costs	$ 201,400,000
Subsequent Event | Over-Allotment Option
Subsequent Event [Line Items]
Shares issued in transaction (in shares)	1,500,000
Oxford Finance Loan | Medium-term Notes
Subsequent Event [Line Items]
Outstanding loan amount		0	$ 14,965,000
Oxford Finance Loan | Medium-term Notes | Subsequent Event
Subsequent Event [Line Items]
Payments of debt fees	$ 1,900,000
2020 Notes Agreement | Convertible Debt
Subsequent Event [Line Items]
Outstanding loan amount		29,754,000
Accrued interest		$ 800,000
2020 Notes Agreement | Convertible Debt | Subsequent Event
Subsequent Event [Line Items]
Outstanding loan amount	33,000,000
Accrued interest	$ 800,000
Shares issued upon conversion of debt (in shares)	2,561,484
Conversion price per share (in dollars per share)	$ 13.20

Uncategorized Items - lung-2020

Label	Element	Value
Restricted Cash, Current	us-gaap_RestrictedCashCurrent	$ 0
Restricted Cash, Current	us-gaap_RestrictedCashCurrent	$ 231,000